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ABSTRACT 
 
AARON MARK WENDELBOE: The Transmission of Bordetella pertussis to Young 
Infants: Identifying Close and Casual Contact Sources 
(Under the direction of Annelies Van Rie) 
 
 
Background: Pertussis is increasingly recognized as a public health concern among infants 
too young to be vaccinated despite widespread vaccination. Valid estimates of who infects 
young infants with Bordetella pertussis are unavailable because previous studies did not 
identify source cases for 47% to 60% of infant cases. Furthermore, the proportion of 
transmission due to casual contact among those with unidentified sources remains unknown. 
 
Methods: A prospective multi-center study was conducted of laboratory confirmed infant 
pertussis cases (aged ≤ 6 months) and their close contacts in France, Germany, the U.S. and 
Canada from February 2003 through September 2004. A comprehensive diagnostic 
evaluation was performed on all participants independent of symptoms. Complete case and 
multiple imputation (MI) analyses were used to address missing data among participants and 
non-participants. Source cases were identified and described by relationship to the infant, 
age, and household status. 
 
Results: The study population comprised 95 index cases and 460 contacts. The source of 
pertussis was identified for 66% and 69% of infants using MI and the complete case analysis, 
respectively. In the primary analysis, parents accounted for 55% of source cases, followed by 
 ii 
 siblings (16%), aunts/uncles (10%), friends/cousins (10%), grandparents (6%), and part-time 
caretakers (2%). The estimated distribution of source cases with close contact was robust to 
changes in the source case definition in sensitivity analyses. However, the proportion of 
transmission due to casual community contact was sensitive to changes in the incubation and 
infectious periods used in the source case definition, and sensitive to allowing transmission 
from those with asymptomatic laboratory confirmed infection, resulting in estimates ranging 
from 20% to 48%. 
 
Discussion: This study provides evidence that among infants for whom a source case was 
identified, household members were responsible for 76% to 83% of transmission of B. 
pertussis to this high-risk group. Also, transmission from casual community contact accounts 
for an appreciable proportion of transmission to young infants. Vaccinating adolescents and 
adults with close contact to infants may be an important strategy in reducing the incidence of 
infant pertussis if high coverage rates can be achieved. 
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I. INTRODUCTION 
A. Pertussis as a public health concern 
 
In the early to mid 1900’s, pertussis (whooping cough) caused more deaths during the 
first year of life than measles, diphtheria or scarlet fever1. Since introducing the diphtheria-
tetanus-pertussis whole cell (DTPw) immunization in the late 1940s, the incidence of 
pertussis in the U.S. dropped 99% by 19762. However, despite continued public health efforts 
to control pertussis in the U.S., in 2004 it was acknowledged to be the least well-controlled 
reportable vaccine-preventable disease3 and the overall reported incidence was 8.9/100,000 
population4, the highest incidence in the past 40 years. Figure 1.1 clearly demonstrates the 
trend of increasing incidence in all age groups5. An acellular pertussis vaccine was licensed 
to replace the whole cell vaccine for infants in 19976. 
Currently in the U.S., infants receive their primary series of acellular pertussis 
vaccine6 at two, four, and six months of age. Booster doses are given at 18 months and 
school entry (4-6 years of age). Immunity is thought to last about 10 years7, 8, such that by 
adolescence much of the population is likely susceptible to pertussis infection. Despite 
widespread vaccination coverage (i.e., 95% for the primary series9), the incidence of reported 
infant pertussis tripled in the past two decades from 34.2 cases/100,000 in the 1980s to 103.5 
cases/100,000 infant population in 200310, 11. Of all cases in infants younger than 1 year of 
age, 53% occurred in the age group < 2 months (no vaccination) and 29% in the 2 to 6 month 
age group (incomplete vaccination)11.  Furthermore, in the 1990s pertussis in young infants 
 was responsible for more than 60% of pertussis related complications, 86% of 
hospitalizations and 92% of all pertussis related deaths in the U.S.5.  
Recent data indicate that adolescents and adults play an increasingly important role in 
the epidemiology of pertussis12-15 as individuals aged 20 years and older account for 23% of 
all reported pertussis cases16. Even though the largest increase in pertussis notification rates 
have been in adolescents and adults, the incidence rate remains highest in young infants.  In 
2002, the age-specific incidence rate per 100,000 population was 109 in infants from birth to 
five months, followed by 15.4 in infants six to eleven months, 8.9 in children aged one to 
four years, 4.8 in children aged five to nine years, 7.0 in persons aged 10 to 19 years, and 1.2 
among adults aged 20 years and older16.   
One strategy for reducing the incidence of pertussis in infants too young to be fully 
vaccinated is indirectly protecting them by increasing herd immunity. This may now be 
accomplished as two acellular pertussis booster vaccines were licensed in the United States 
in 2005: one for adolescents (Boostrix, GlaxoSmithKline) and one for adolescents and adults 
(Adacel, sanofi pasteur)3. The Advisory Committee on Immunization Practices (ACIP) 
recently recommended that all persons 11 to 18 years should be vaccinated with a single dose 
of Tdap (tetanus toxoid, reduced diphtheria toxiod, and acellular pertussis vaccine) and that 
adults should receive Tdap in place of Td (tetanus and diphtheria toxoids vaccine) every 10 
years3.  The effect of this strategy on infant pertussis has been modeled and shown to 
critically depend on the vaccination coverage achieved among those that come in contact 
with young infants17; however, the transmission dynamics of pertussis to young infants 
remains uncertain. 
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 B. Statement of purpose 
 
The purpose of this dissertation is to describe the epidemiology of pertussis with a 
focus on its transmission to young infants. This will be accomplished by identifying the 
source of transmission to young infants among those with close contact to them. 
Additionally, the assumption that close contact is necessary for pertussis transmission to 
occur will be investigated by estimating the amount of transmission due to casual contact 
with community members. Also included in this dissertation are thorough reviews of the 
following topics: state-of-the-art methods in diagnosing pertussis, duration of immunity 
against Bordetella pertussis due to natural infection and vaccination, and the role of maternal 
anti-pertussis antibodies in the protection of young infants against pertussis. 
More precisely identifying who infects young infants with pertussis will aid public 
health decision makers design effective vaccination strategies to reduce the incidence of 
infant pertussis. It will also contribute to better understanding the current epidemiology of B. 
pertussis by more clearly describing the role casual contact plays in the transmission of 
pertussis to young infants. 
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 Figure 1.1. Number of reported pertussis cases, by year, in the United States - 1980 to 2004. 
Data from Centers for Disease Control and Prevention5, 18, 19. 
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II. REVIEW OF THE LITERATURE 
 
A. Role of adults and adolescents in the transmission of B. pertussis to infants 
 
Adults and adolescents are a common source of infection for infants1-5 (Table 2.1). 
Two recent studies in the U.S. and France used surveillance data to identify the source of 
pertussis in young infants. Both studies relied on clinical case definitions (without laboratory 
confirmation) to make pertussis diagnoses among contacts to the index case. In the U.S. 
study conducted from 1999 to 2002 of infants less than one year, four states participated in 
enhanced pertussis surveillance. Source cases were defined as anyone with an acute cough 
preceding the incubation period of pertussis illness. A source case was identified in 43% of 
the 616 infant cases. Among these, parents accounted for 46.8% of the sources of infection, 
of which 68% were mothers3. In the French study from 1996 to 2001, a source of infection 
was identified for 53% of infants, of which 56% were parents, 23% were siblings, and 19% 
were identifiable non-household contacts with close contact to the index case6.  
A more thorough, yet smaller, study of 33 infants in the UK collected biologic 
specimens to allow for laboratory evaluation of close contacts to hospitalized infants less 
than 5 months old. Diagnostic specimens were obtained from 81% of the adult contacts and 
43% of the child contacts. Source cases were identified as the contact with the earliest onset 
of illness compatible with pertussis and an epidemiologic link to an infant pertussis case. A 
source case was identified for 42% of index cases, of which the parent was identified as the 
source for 42%. Of the primary cases, 67% were laboratory confirmed2.  
 Two studies, although not specifically designed to study the transmission of B. 
pertussis to young infants provided estimates on the sources of infection as part of their 
secondary aims. In a vaccine efficacy trial in Germany, bi-weekly calls to the parent/guardian 
of each infant enrolled in the trial were made to document any cough >7 days that were not 
improving in all family members. Specimens for culture and serology were collected for ill 
family members; polymerase chain reaction (PCR) samples were collected during the last 
few months of the study. Of all infant and childhood cases of pertussis for whom a source 
was identified, an adult was found to be the primary case for 48%1.  In a Canadian study of 
hospitalized infants less than one year of age, a parent was determined to be the source of 
infection for 20% of the infants where a source was identified for 39.8% of all infants. Most 
source cases were determined by clinical symptoms (89%) and only 7.5% of sources were 
confirmed by culture4.  
Finally, an earlier study in the U.S. of 233 bacteriologically confirmed pertussis cases 
in infants and children during two six year periods, 1965 to 1971 and 1972 to 1977, provided 
evidence that the most common source of transmission shifted from children in the first 
period to adults in the second period5. Specifically, in the first time period children were 
identified as the source for 46% of the index cases while adults accounted for only 12.5%. In 
the second time period, children were the source for only 9% of infections and adults were 
the source for 55% of infections. The method used to determine the source of infection was 
based only on symptoms. While the results from this study should be interpreted with 
caution, it should be noted that the incidence of pertussis was decreasing in all age groups 
until 1976 and the results from this study may help illustrate some of the changes in the 
 8 
 epidemiology of pertussis in a time period when vaccination was affecting the reservoirs of 
B. pertussis in the community. 
While these studies contribute meaningfully to our understanding of who infects 
infants with B. pertussis, each of these studies used different study populations, case 
definitions, and methods to follow-up contacts and has their respective limitations as outlined 
above. An important limitation common to all of these studies is that the source of infection 
could not be identified in 47-60% of cases included in these studies, rendering the 
interpretation of the role of identified close contacts in the transmission of B. pertussis to 
young infants problematic. Among infants for whom a source case was not identified, it is 
unknown whether transmission came from within or without the household or from persons 
with close or casual contact. Furthermore, if transmission came from within the household, it 
is unknown how similar the distribution of source cases is to those infants for whom a source 
was identified.   
B. Transmission from casual contact 
 
It is unclear how efficiently B. pertussis is transmitted due to casual contact. The 
identification of transmission to and from index cases (in trace-back investigations2-4, studies 
identifying the efficacy of providing antibiotic prophylaxis7-9 to exposed persons, etc.) 
focuses on close contacts. While this is due to the impracticality of identifying the numerous 
casual contacts an index case may have, the result is an implicit belief that transmission from 
casual contact is a negligible concern.   
B. pertussis is reported to be among the most contagious pathogens in humans as an 
average of 15 secondary infections arise from a single case10 implying transmission from 
casual contact is possible. Pertussis is most often spread via direct contact with aerosolized 
 9 
 droplets that travel approximately 3-4 feet due to coughing, sneezing, and talking from an 
infectious source11, 12. This does not discount casual contact since closeness of contact is a 
function of not only proximity, but also frequency, and duration. For example sitting within 4 
feet of an infectious person on the bus (even for an extended period of time) is likely to be 
considered casual contact. 
Unfortunately none of the studies which aimed to identify the source of infection 
among infants1-4, 13 attempted to estimate the amount of transmission due to casual contact 
from the community. In these studies, no analyses to account for missing data were 
conducted so that among infants for whom a source was not identified, it is impossible to 
distinguish the proportion of transmission due to casual contact from the proportion where 
missing data among close contacts interfered with identifying the source3. The only available 
estimate of the proportion of transmission due to casual contact is from the pre-vaccine era in 
which Luttinger reported that at least 5-14% of pertussis was due to community acquired 
infection14.  
C. Obstacles to identifying the source of transmission 
 
Missing data and poor sensitivity of the primary case definition are among the most 
likely reasons for the low success rate in identifying the source case of pertussis to young 
infants. Other potential reasons include insufficient sensitivity in available diagnostic 
methods and the possibility that asymptomatically infected persons can transmit pertussis. 
This underscores the necessity of collecting diagnostic information using multiple diagnostic 
methods and the need to include all close contacts (including those with mild pertussis or 
asymptomatic infection) if one aims to understand the route of pertussis transmission.  
 10 
 1. Missing data 
 
The most important obstacle in identifying the amount of transmission from casual 
contact is due to missing data. Missing data is a common problem to essentially all 
epidemiologic research and occurs in two general forms: unit non-response (non-
participation) and item non-response (missing information among participants). Missing data 
of both kinds can be generated by three types of missing data mechanisms: missing 
completely at random (MCAR), missing at random (MAR), and not missing at random 
(NMAR). MCAR means that missingness does not depend on the values of the data, either 
observed or missing, and is typically the best scenario as estimates made from complete case 
analyses accounting for these missing data will result in estimates that are unbiased, albeit 
less precise than if the data had not been missing. The MAR missing data pattern means that 
missingness may depend on the values of the observed data, but not on the missing data. 
When a complete case analysis is conducted to address missing data that are MAR, in 
addition to being less precise, estimates may be biased if not properly controlled for by 
adjusting for the observed variable associated with being missing. Both the MCAR and MAR 
missing data mechanisms may be described as ignorable since the unknown distribution of 
missing data is not dependent on the missing data. However, when missingness depends on 
the missing value, the missing data pattern is NMAR (or non-ignorable) and an informed 
mechanism causing the missingness is necessary to properly analyze the data15.  
 There are a number of analytical methods available to account for missing data. One 
of the most common methods is the complete case analysis which confines the analysis to the 
set of cases with no missing values for main effects and covariates. While the major 
advantage is its simplicity, it may produce biased estimates if the missing data mechanism is 
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 not MCAR15. Multiple imputation (MI) is a more sophisticated method that does not require 
the assumption that missing data be MCAR. In simple settings it lends itself to the relaxed 
assumption that missing data are MAR. If the missing data mechanism is NMAR, MI can 
still be used, but information must be available to specify how the missing data are 
generated. One method of conducting MI involves calculating the predicted probability that a 
missing data point is equal to a given value conditioned on the observed data. A unique value 
is imputed for a specified number of iterations, creating m multiply imputed datasets. The 
imputed value may differ across each imputed dataset, but when averaged over the m 
complete datasets the imputed value will be unbiased assuming the specified missing data 
mechanism is correct15.   
 Missing data from both non-participation and lack of critical information to make 
pertussis diagnoses among participants is a limitation to studies aimed at identifying the 
source of infection. Among those infants for whom a primary case was not identified, it is 
difficult to know how many primary cases would have been identified had the data not been 
missing. Previous studies have made no explicit assumptions about the missing data 
mechanism. Furthermore, how missingness was accounted for in the analyses was not clearly 
described as there are different types of complete case analyses possible. As a result, no 
inferences have been made regarding the source of transmission among infants where no 
source case could be identified. Thus, a statistically valid method accounting for missing data 
is an important component of future studies aimed at identifying the source of pertussis to 
young infants.   
2. Primary case definitions: duration of the incubation and infectious periods 
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 Poor sensitivity of the primary case definition for pertussis is likely another obstacle 
to identifying the source case for infant index cases of pertussis. In studies of disease 
transmission, the index case is the first case that comes to the attention of health providers. 
The primary (source) case is the person who transmitted the disease to the index case. A co-
primary case is a case that was infected at a time indistinguishable from the index case and 
determined to have the same primary case as the index case. Secondary cases are cases 
infected by the index case (or co-primary cases). The development of these definitions is 
based on the incubation and infectious periods16. The incubation period is the time from 
infection to symptom onset and the infectious period is the time during which an individual 
can transmit infection. 
 The incubation period for pertussis is frequently cited as seven days11, 17-19, but has 
been reported to be as short as two days19 and as long as 30 days20. Thus, to maximize 
specificity and sensitivity, seven days has traditionally been used as the minimum number of 
days between symptom onsets in two consecutive cases.  
 The infectious period for pertussis is frequently cited to be three weeks17, 20 but can 
last as long as five weeks20. The most infectious period is reported to be during the first week 
of illness18 and gradually declines thereafter until the fifth week20. In an effort to maximize 
specificity and sensitivity, three weeks is most commonly used as the duration of 
infectiousness.  
Using the average incubation and infectious periods above, most case definitions of 
primary cases of pertussis require that symptom onset in the primary case occur 7 to 28 days 
before symptom onset in the index case21-23. The strength of this case definition lies in its 
specificity rather than its sensitivity. The application of a more sensitive case definition using 
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 a shorter incubation period and a longer infectious period is supported by a study of 
sequential pertussis cases within the same household using cough-plates to measure 
infectiousness19. From the distribution of time intervals between two sequential household 
cases (shown in Figure 2.1), it was determined that allowing symptom onset to occur 2 to 48 
days in the primary case before symptom onset in the index case was justified. 
3. Pertussis, a diagnostic challenge 
 
Another potential difficulty in identifying the source case of pertussis for index cases 
is the complexity in making an accurate diagnosis. According to the World Health 
Organization (WHO) and the Centers for Disease Control and Prevention (CDC) a clinical 
diagnosis of pertussis can be made in a patient with a cough lasting two or more weeks with 
at least one of the following: paroxysms of coughing, inspiratory whoop, or post-tussive 
vomiting, without other apparent cause24, 25. Laboratory confirmation should be sought using 
PCR and/or culture24, and serology techniques are also available.  
Accurately diagnosing pertussis disease is often challenging because many cases of 
pertussis have atypical presentations26, 27 and the sensitivity of both culture and PCR decrease 
with disease progression, especially by the time pertussis is clinically suspected28, 29. 
Following is a brief summary of the diagnostic challenges in diagnosing pertussis.  For a 
more detailed evaluation of the state-of-the-art diagnostic methods, refer to Chapter VII. 
In the pre-vaccine era, using the classic symptoms of inspiratory whoop and 
paroxysmal cough was generally sufficient to diagnose pertussis for clinical purposes. 
However, vaccination against pertussis has changed the epidemiology and presentation of 
disease to such a great extent that clinical signs and symptoms can no longer be relied upon 
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 to make accurate diagnoses, especially in  persons with mild disease and infants with severe 
disease30, 31.  
Culture, the traditional “gold standard”7, has low (12-60%) sensitivity28, 32-36. This 
poor sensitivity is mainly due to the difficulty in isolating the organism at the time typical 
pertussis symptoms appear28, 37 and the fact that B. pertussis is a fastidious grower37, 38. 
Since the 1990’s, PCR has gained popularity as a diagnostic tool, both in clinical and 
research settings and is beginning to replace culture as the gold standard7. The greatest 
advantage PCR has over culture is its higher sensitivity, ranging from 70 – 99%28, 29, 33, 34, 36, 
39, 40; though as with culture, sensitivity decreases with time since infection29, 41. Important 
limitations of PCR are that no internationally accepted standardized methodology exists nor 
is there an approved kit by the U.S. Food and Drug Administration, resulting in the use of a 
multitude of techniques with varying sensitivities and specificities. However, reports from 
the Global Pertussis Initiative suggests that progress is being made to make the IS481 target 
the international standard42. 
Serologic methods to diagnose pertussis have mostly been used in research settings as 
the time needed to make a diagnosis is not practical in most clinical contexts. Of the multiple 
criteria available, a four-fold rise in anti-pertussis antibody titer26, 29, 43-45,  the most specific 
and least sensitive criterion, is most commonly used. A major limitation of paired serology is 
the interpretation is dependent on correctly timing the collection of both the acute and 
convalescent sample.  
Due to the challenges in obtaining paired sera, recent efforts have resulted in the 
definition of a single antibody titer suggestive of recent pertussis. A study by de Melker in 
200043 demonstrated that a level of 100 Dutch ELISA Units (DEU) of anti-pertussis toxin 
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 IgG was 76.4% sensitive and 99.2% specific for recent pertussis infection. An important 
limitation to this approach is the lack of standardized ELISA units across different 
laboratories and different countries. In the U.S., Massachusetts is the only state with the 
laboratory capability to make pertussis diagnoses using a single titer46. One important step to 
resolving these differences has been made by the European Sero-Epidemiology Network47 
(ESEN) in which cutoffs for Dutch units can be directly compared to French, British, 
German, Swedish, and Italian units. A similar cut-off of 96 EU/mL has recently been 
suggested for use in the U.S.48 
4. Asymptomatic infection 
 
The potential role of asymptomatically infected persons transmitting pertussis to 
young infants is controversial, but nonetheless may contribute to the inability of previous 
studies to identify source cases to infant pertussis cases3. Issues surrounding asymptomatic 
infection are complex. While cases of laboratory confirmed asymptomatic infection have 
been well-documented49, 50, the long term “carrier” state is not believed to exist11, 51, 52. 
Furthermore, dogma holds that asymptomatically infected persons are an insignificant source 
of infection since without a cough, they do not efficiently spread infectious aerosol droplets 
to others11, 12, 16. While this may be true at the population level, this assumption should be 
more closely examined in the context of infant pertussis3. For example, a mother 
asymptomatically infected with pertussis may have very close contact with her infant, 
including activities such as kissing, cuddling, singing, and sharing of utensils and food. In 
these settings of close contact where respiratory secretions may be shared, it is plausible that 
transmission may occur. Thus, in the absence of an identifiable symptomatic source of 
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 infection but in the presence of a laboratory confirmed asymptomatic case, the possibility of 
transmission from the asymptomatic case should be considered.  
D. Summary 
 
Pertussis among infants too young to be fully vaccinated is an increasing concern in 
the U.S. due to the increasing incidence in all age groups. The effect recent recommendations 
to boost the immunity of adolescents and adults against pertussis on infant pertussis has been 
shown to depend on who infects young infants, yet these transmission dynamics remain 
uncertain. Further, the amount of pertussis transmission due to close contact vs. casual 
contact is unknown. Previous studies describing the distribution of source cases of pertussis 
to young infants have the following limitations: a source case was not identified for 47-60% 
of all infant index cases, pertussis diagnoses have not been uniformly made using state-of-
the-art diagnostic tools, missing data among participants and non-participants impede the 
ability to make inferences regarding transmission from casual contact, insensitive primary 
case definitions may result in failing to identify the source case, and the role of transmission 
of asymptomatically infected persons is unknown. The net effect of these limitations results 
in a large proportion of infant index cases of pertussis for who the source of transmission is 
unknown. In order to better estimate who transmits pertussis to young infants and the amount 
of transmission due to casual contact in the community, it is necessary to conduct a study 
capable of addressing and, where possible, overcoming the above limitations. 
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 Figure 2.1. Frequency distribution of time interval in days between two successive pertussis 
cases in the same household (from Stocks, 193334).  
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Table 2.1. Comparison of studies estimating the source of infection to infants. 
 Renacoq 20056 Bisgard et al. 
20043 
Crowcroft et al. 
20032 
Halperin et al. 
19994 
No. of index cases 1519 616 33 1082 
Age range <6 mo <1 yr <5 mo <1 yr 
% of index cases with identified source  53 43 42 40 
Source of pertussis     
  Parent (%) 56 47 42 20 
  Sibling (%) 23 20 NA 53 
  Non-household* (%) 19 26 NA 20 
Laboratory confirmation in index case** (%) 84 Some† 100 Some†
Diagnostic method in contacts     
  Symptoms Yes Yes Yes Yes 
  Culture No No Yes Some‡
  PCR No No Yes No 
  Serology No No Some†† No 
Design type Prospective 
surveillance 
Retrospective 
surveillance 
Prospective case 
enrollment 
Retrospective 
surveillance 
19 
NA – Not available 
*Identifiable contacts among non-household members. 
**Laboratory confirmation included culture, polymerase chain reaction (PCR), and/or serology. 
†Data not available, but assumed that some proportion of diagnoses in index cases of pertussis were laboratory confirmed. 
††Single serology taken for adult contacts only, stored serum samples used for mothers where available. 
‡7.5% of contacts were verified by culture. 
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III. STATEMENT OF SPECIFIC AIMS 
A. Aim One 
 
Aim: Determine the proportions of B. pertussis infection transmitted to young infants 
from possible source case groups, including mother, father, sibling, non family member, etc. For 
each index case of infant pertussis, a comprehensive diagnostic evaluation was performed on all 
relevant contacts to determine the source case of pertussis most probably responsible for 
transmission of B. pertussis to the infant.   
Rationale: Identifying the type of persons responsible for transmission of B. pertussis to 
young infants will enable us to design strategies aimed at reducing the burden of infant pertussis. 
This is especially timely given the recent efforts to license the acellular pertussis vaccine for 
adolescents and adults. 
Hypothesis: Household members, particularly parents and adolescents, play an important 
role in the transmission of pertussis to young infants. A source case will be identified for a 
greater proportion of infant index cases than has previously been accomplished. 
 
B. Aim Two 
 
Aim: Determine the proportion of B. pertussis transmission to young infants due to casual 
contact from the community. Missing data will be accounted for using a complete case analysis 
and a multiple imputation analysis.  
 Rationale: Missing data is an important limiting factor in identifying the source of 
pertussis transmission to young infants. Current estimates of the proportion of infants infected 
from casual contact from the community are not available. Additionally, there is uncertainty 
surrounding the role of casual contact in pertussis transmission as the focus has traditionally been 
on close contact. 
Hypothesis: By accounting for missing data using multiple imputation, a greater 
proportion of source cases will be identified supporting the theory that pertussis infection in 
young infants is mostly due to transmission from close contacts. 
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IV. METHODS 
A. Study design 
 
We designed a prospective epidemiological, multi-center, study conducted in 14 hospitals 
in four countries: France, Germany, the U.S. and Canada from February 2003-September 2004. 
Four hospitals in France (Hôpital Jean Verdier, Bondy; Hôpital Edouard Herriot, Lyon; Hôpital 
Robert Debré, Paris; and Hôpital Armand Trousseau, Paris), four hospitals in Germany (Dr. von 
Haunersches Kinderspital, Kinderklinik der Technischen Universitat, Kinderkrankenhaus 3. 
Orden, Kinderklinik Harlaching, Munich), three hospitals in the U.S. (Baylor College of 
Medicine, Houston; Children’s Hospital of Pittsburgh, Pittsburgh; and Cincinnati Children’s 
Hospital Medical Center, Cincinatti) and one hospital in Canada (IWK Health Centre, Halifax) 
participated. Data analysis was performed at the Department of Epidemiology, the University of 
North Carolina at Chapel Hill (UNC). Institutional Review Boards at each site and UNC 
approved the study. 
B. Source population and data collection 
 
Three categories of participants were included in the study: infant index cases, household 
contacts, and close non-household contacts. Index cases eligible for the study were all 
unvaccinated or partially vaccinated infants less than seven months of age diagnosed with 
laboratory (culture or polymerase chain reaction (PCR)) confirmed pertussis at one of the 
participating study sites. Household contacts of the index cases were defined as persons living in 
 the same residence as the infant index case during the month preceding the diagnosis of pertussis 
in the infant.  
Non-household contacts were eligible for study participation if they were in contact with 
the child during the month prior to the onset of disease in the infant index case and fulfilled one 
of the following criteria: 1) full-time caretaker (>30 hours/week) of the infant index case or 2) a 
person with an acute cough illness lasting at least seven days in the month prior to the diagnosis 
of pertussis in the infant index case and had contact with the infant index case during the 
symptomatic period. Participants were excluded if their residence was distant from the study site 
(determined on a case by case basis) or in case of the death of an index case.  
A parent or legal guardian of the infant index case was contacted by study personnel for 
enrollment as soon as possible (but no more than 7 days) following a laboratory confirmed 
pertussis diagnosis in the infant index case. Following informed consent, a standardized 
questionnaire was administered in person to the parent/legal guardian of each index case eliciting 
information regarding eligibility, clinical history, household structure, and potentially eligible 
non-household contacts. The following demographic and clinical information were collected: 
date and country of birth, gender, pertussis vaccination status, type and duration of symptoms 
due to pertussis, laboratory tests performed and results thereof, number of hospitalization days 
(specified by ward type), number of visits to health care providers, family composition, type of 
child care, and contacts with symptoms of an acute respiratory illness (cough) who had been in 
close contact with the child during the month preceding the onset of symptoms in the infant 
index case. 
All household members of the infant index case were invited for participation in the study 
and recruited upon informed consent. Within one week of the pertussis diagnosis in the infant, 
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 consenting household members were interviewed face-to-face using a standard questionnaire to 
obtain demographic and clinical data. A respiratory sample (nasopharyngeal aspirate or 
nasopharyngeal swab) was taken for culture and PCR detection of B. pertussis. An acute blood 
sample was taken (3 ml for participants 2 years or older, 1.5 ml for participants <24 months of 
age) for IgG and IgA anti-pertussis toxin antibody (anti-PT) detection by Enzyme-linked 
Immunosorbent Assay (ELISA). Adults were asked to provide the information for their children. 
The questionnaire elicited information of all household members concerning: date of birth, 
gender, pertussis vaccination and disease history, average daily duration of close contact 
(playing, cuddling, feeding, etc.) with the index case, occurrence, duration and type of 
respiratory symptoms (coryza, sneezing, cough) during the month preceding the onset of 
symptoms of the index case, and antibiotic use for these respiratory problems. Data regarding 
occupation, presence of known pertussis cases in colleagues, and the number of lost work days 
due to illness in the index case were collected on all adult household members. Child household 
contacts were asked to provide data regarding school attendance and day care. At the second 
visit, a convalescent serum sample was drawn and data were collected relating to cough and 
cold-like symptoms since the first visit and any lost work since the first visit. Household 
members who failed to attend a study visit appointment were contacted to schedule a home visit 
for interview and sample collection. 
Potential non-household sources of infection were identified during the interview with 
the parent(s)/legal guardian of the infant index case. The person was contacted by telephone 
following permission of the parent/legal guardian. Upon verbal consent, the person was 
interviewed via telephone using a standardized questionnaire. Those meeting the eligibility 
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 criteria were invited for an in-person study visit and followed the same study protocol as for 
household contacts. 
C. Diagnostic laboratory procedures and quality control 
 
PCR samples were analyzed at the local lab using site specific protocol and stored at -
80°C. Acute and convalescent serum samples for IgG and IgA antibodies to pertussis toxin (PT) 
were stored at -20°C. All culture, PCR and serum samples were sent frozen to the French 
Reference Laboratory for Whooping cough and other Bordetelloses of  Institut Pasteur in Paris. 
PCR samples were analyzed by Real-time PCR using the IS481 target  according to the 
recommendations of the European consensus meeting1 and following the methods as reported by 
Kosters et al.2 and described below.  
DNA extraction of bacterial suspensions was done with the QIAamp DNA Mini 
Kit (Qiagen, Hilden, Germany) after proteinase K treatment according to the 
manufacturer’s protocol. Basic reagents for the LightCycler PCR were purchased from 
Roche Diagnostics, Mannheim, Germany. Oligonucleotides (TibMolBiol, Berlin, 
Germany) from IS481 and IS1001 for B. pertussis and B. parapertussis, respectively, 
were adopted from the work of Reischl et al. (23) (Table 1). The 20-_l reaction mixture 
volume in a glass capillary tube contained 4 mM MgCl2, 2 _l of FastStart Reaction Mix 
Hybridization Probes (component of the FastStart DNA Master Hybridization Probes kit; 
Roche Diagnostics), 2 _l of DNA extract, and primers and probes depending on the PCR 
format. For the simplex format 0.5 _M (each) primers BP-1 and BP-2 or BPa-1 and BPa-
2 and 0.2 _M (each) matching probes were used; for the duplex format 0.5 _M 
concentrations (each) of the four primers; 0.2 _M (each) probes BP FLU, BP LCR, and 
BPa-HP-1; and 0.4 _M probe BPa-HP-2 were used. 
 
Reaction conditions for the three assays were chosen according to a standard 
LightCycler protocol in our laboratories and were 10 min at 95°C, followed by 40 cycles 
of 10 s at 95°C, 10 s at 65°C, and 20 s at 72°C. Fluorescence increase, i.e., creation of 
specific product, was measured during the annealing step at 65°C. A melting curve 
analysis was performed after the last amplification cycle with 95°C 
for 0 s, 45°C for 30 s, and 95°C for 0 s. Temperature change rates were 20°C/s for all but 
the last step, where the rate was 0.1°C/s. Readout of LC-Red 640 values (B. pertussis) 
was performed in channel F2/Back-F1, and readout of LC-Red 705 values (B. 
parapertussis) was performed in channel F3/Back-F2. A sample was regarded as positive 
when the LightCycler software version 3.5 determined a crossing point in the 
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 quantification analysis screen and the PCR product produced a characteristic melting 
curve with a discernible peak at 63°C for B. pertussis and at 69°C for B. parapertussis in 
the melting curve screen. 
 
Serum samples were analysed using the standardised enzyme-linked immunosorbent 
assay (ELISA) to quantify IgG anti-PT, as previously described2 and using purified PT from 
Sanofi Pasteur (Gift of Marie-José Quentin Millet). Assay cut-off was set at ≥ 20 EL U/ml. The 
results from IP were favored in instances of discrepant results. 
D. Case definitions 
 
Participants were classified into one of four outcome categories: 1) laboratory confirmed 
symptomatic case of pertussis, 2) epidemiologically linked case of pertussis, 3) laboratory 
confirmed asymptomatic infection, and 4) not infected. Outcomes were assigned using a case 
definition algorithm (Figure 4.1). Laboratory confirmed symptomatic cases of pertussis reported 
symptoms of cold or cough and met one of the following criteria: positive culture or PCR of 
nasopharyngeal aspirate or swab for B. pertussis, a ≥ 4-fold change in IgG titer to PT between 
acute and convalescent serum samples (as measured by ELISA), or a single anti-PT IgG 
antibody titer ≥125 EU/ml.  
Epidemiologically linked cases were defined as those who had contact with the infant 
index case in the month preceding symptom onset in the index case, had an acute cough illness 
lasting ≥ 2 weeks, and no laboratory confirmed pertussis3. Laboratory confirmed asymptomatic 
cases of pertussis met the same criteria as laboratory confirmed symptomatic cases, but did not 
report any cough or cold symptoms. Those classified as uninfected failed to meet any of the 
above criteria. 
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 Subsequent to pertussis infection classification, the most probable source of transmission 
was identified using a primary case definition. Two separate definitions for primary cases were 
developed and employed. The more traditional and specific primary case definition required 
symptom onset in the primary case to occur 7 to 30 days prior to symptom onset in the index 
case4-6 and was used as the principle case definition in addressing Aim One. An alternative, more 
sensitive case definition, expanded the time interval by allowing symptom onset in the primary 
case to occur 2 to 48 days7 prior to symptom onset in the index case and was used as the 
principle case definition in addressing Aim Two. When multiple primary cases reported 
symptom onset on the same date, no distinction was made unless one was a confirmed case and 
one was epidemiologically-linked, in which case the confirmed case was identified as the 
primary case.  
E. Sample size 
 
This study was designed to enroll 100 infant cases of pertussis and anticipated on average 
4.5 contacts for each index case. We estimated that 65% of all diagnosed pertussis cases would 
agree to participate in the study and that 75% of those enrolled would complete the study.  
 
F. Methods pertaining to Specific Aim One 
 
Aim One: The transmission of Bordetella pertussis to young infants. Determine who (i.e., 
mother, father, sibling, non family member, etc.) transmits B. pertussis infection to young 
infants. For each index case of infant pertussis, a comprehensive diagnostic evaluation was 
performed on all relevant contacts to determine the primary case of pertussis most probably 
responsible for transmission of B. pertussis to the infant.   
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 1. Principle analysis 
 
The principle analysis consisted of a complete case analysis in which contacts missing 
critical diagnostic information (i.e., no PCR specimen and/or no serum sample) were excluded 
from the analyses. Primary cases were defined using the more specific/traditional case definition 
that symptom onset must occur 7 to 30 days before symptom onset in the index case. Twin infant 
index cases were treated as a single case.  
2. Sensitivity analysis 
 
In order to determine the impact of missing data on the study results two sensitivity 
analyses were conducted. In a highly conservative analysis, the strict complete enrollment 
analysis, the entire family was excluded if one or more household and non-household contacts of 
the index case were not enrolled or missing critical diagnostic data. In a less restrictive analysis, 
the all participant analysis, data on all participants were taken into account. To allow for missing 
PRC and/or serology results, pertussis outcome classification was assigned to each participant 
using the case definition algorithm (Figure 4.1) based on the diagnostic information available for 
each person.  
Additional sensitivity analyses investigated potential reasons why source cases could be 
missing for some infants, despite complete enrollment and diagnostic investigation. In the 
expanded primary case definition analysis, the onset of symptoms for primary cases was 
expanded to 2 to 48 days prior to symptom onset in the index case. In the asymptomatic case 
analysis, asymptomatic laboratory confirmed cases were included as potential source cases8 in 
families where no symptomatic primary case (using the expanded primary case definition) could 
be identified.  
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 3. Statistical analysis 
 
Statistical analyses (Mantel-Haenzel Chi-square tests) were conducted using SAS 9.1.3 
(Cary, NC). Results from sensitivity analyses were not compared to the primary analysis using 
statistical tests as they are neither entirely independent nor entirely dependent samples, thus 
violating the assumptions required of standard statistical tests. 
G. Methods pertaining to Specific Aim Two 
 
Aim Two: Estimating the role of casual contact from the community in transmission of 
Bordetella pertussis to young infants. Determine the proportion of B. pertussis transmission to 
young infants due to casual contact from the community. Missing data will be accounted for 
using complete case and multiple imputation analyses.  
1. Missing data analyses: complete case and multiple imputation 
 
The complete case analysis was composed of households where complete enrollment of 
the household was achieved and each household member and enrolled non-household contact 
had complete diagnostic data (i.e., information regarding symptoms and results from PCR and at 
least one serum sample).  
Since some data were collected on each household member, missing data among non-
participants could be treated as item non-response. The following information was available for 
all participants and non-enrolled household members: relationship to the index case, amount of 
contact with the index case, age, household size, symptoms of cold or cough in the month prior 
to enrollment of the index case, and whether or not the cough lasted at least two weeks. This 
information was used as predictor variables in building the imputation model described below. 
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 Due to the large proportion of household members excluded from the complete case 
analysis, MI was conducted in order to analyze all of the data collected. The imputation model 
utilized logistic regression to predict the probability that each contact with missing data was the 
source case for the index case in that household (Y=1 if a source case, Y=0 if not a source case) 
adapting the methods described by Raghunathan et al.9 for non-sequential logistic regression. 
Profiles incorporating a combination of the above explanatory variables were generated using 
indicator variables. (For example, a parent with a 2+ week cough and contact with the index case 
for >5 hours/day was one profile (X1), a sibling with a 2+ week cough and contact with the index 
case for >5 hours/day was another profile (X2).) Household size (a count variable) was also 
included in the predictive model. To account for uncertainty in the maximum likelihood estimate 
(MLE), unique approximations of the MLE for each parameter estimate were calculated for each 
of 10 imputed datasets. This was accomplished by adding the MLE to the product of the 
Cholesky decomposition of the covariance matrix and a random normal deviate9. A uniform 
random number (0,1) was sampled for each individual with missing data and compared to each 
individual’s predicted probability of being a case, where Y=1 for every probability less than or 
equal to the uniform random number, otherwise Y=010. 
The missing data mechanism was assumed to be ignorable. This assumption cannot be 
explicitly verified with the available data because the response variable (source case status) is not 
observed among those with missing data11. An ignorable missing data mechanism in this study 
means that missingness (i.e., failure to enroll or provide diagnostic specimens) was independent 
of being a source case, conditional on the observed data (age and household status). 
2. Sensitivity analyses 
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 The impact of the source case definition on the ability to identify source cases was also 
assessed. The specificity was increased by assuming a longer incubation period of 7 days and a 
shorter duration of infectiousness of 23 days4, 5, 12-14, thus requiring symptom onset in the contact 
to occur 7 to 30 days prior to symptom onset in the index case.  In an additional analysis aimed 
at increasing the ability to identify source cases, laboratory confirmed asymptomatic cases were 
allowed to be source cases for infants where a source case could not be identified. Thus, the 
outcome value needed to be estimated for all persons with missing data in this sensitivity 
analysis. 
3. Estimate computation and regression analyses 
 
Multiply imputed data were analyzed and standard errors accounting for MI11 were 
calculated in SAS 9.3.1 (Cary, NC).  General estimating equation (GEE) regression was 
conducted since possible clustering within households likely violated the independence 
assumption. In order to overcome non-convergence problems using binomial regression, 
modified poisson regression was used to estimate the log binomial model15. Models were fit to 
the multiply imputed data using forward entry to identify risk factors associated with the 
probability of not identifying a source case among the index cases.
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Figure 4.1. Case definition algorithm for classification of pertussis outcome among contacts to laboratory confirmed infant index cases 
of pertussis. (Booster age range is defined as children aged 3 months through 2 years or 4 years through 7 years.) 
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 A. Abstract 
 
Background: Pertussis vaccination has reduced the number of notified cases from peak 
years by more than 95% in industrialized countries. The effect of recently recommended 
adult and adolescent vaccination strategies on infant pertussis depends, in part, on the 
proportion of infants infected by adults and adolescents. This proportion, however, remains 
unclear since studies have not been able to determine the source case for 47%-60% of infant 
cases. 
Methods: A prospective international multi-center study was conducted of laboratory 
confirmed infant pertussis cases (aged ≤6 months) and their household and non-household 
contacts. Comprehensive diagnostic evaluation (including PCR and serology) was performed 
on all participants independent of symptoms. Source cases were identified and described by 
relationship to the infant, age, and household status. 
Results: The study population comprised 95 index cases and 404 contacts. The source of 
pertussis was identified for 48% of infants in the primary analysis and up to 78% in 
sensitivity analyses. In the primary analysis, parents accounted for 55% of source cases, 
followed by siblings (16%), aunts/uncles (10%), friends/cousins (10%), grandparents (6%), 
and part-time caretakers (2%). The distribution of source cases was robust to sensitivity 
analyses. 
Conclusion: This study provides solid evidence that among infants for whom a source case 
was identified, household members were responsible for 76-83% of transmission of B. 
pertussis to this high-risk group. Vaccination of adolescents and adults in close contact with 
young infants may thus eliminate up to 66% of infant pertussis if high coverage rates can be 
achieved. 
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 B. Introduction 
 
Bordetella pertussis continues to circulate and cause disease even in populations with 
high vaccination coverage of infants and children. Waning of vaccine induced immunity(1-4) 
is cited as an important factor contributing to this persistent problem(5-8). Despite widespread 
vaccination coverage (i.e., 95% for the primary series(9, 10)), the reported incidence of infant 
pertussis in the U.S. tripled in the past two decades from 34.2 cases/100,000 in the 1980s to 
103.5 cases/100,000 infant population in 2003(11, 12). Infants too young to have completed 
their primary vaccine series account for the majority of pertussis related complications, 
hospitalizations, and deaths(12, 13). 
One strategy for protecting infants is to increase herd immunity by vaccinating close 
contacts. France was the first country to introduce a booster dose for adolescents in 1998(14), 
followed by Germany, other European countries, Canada, Australia, and Japan(15). France and 
Germany have also recommended a booster for parents and health care workers in contact 
with young children(14, 16). The U.S. Advisory Committee on Immunization Practices (ACIP) 
recently recommended that all adolescents and adults receive a single booster dose of Tdap 
(tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) in place of Td 
(tetanus and diphtheria toxoids vaccine)(17, 18).  Modeling has shown that the effect on infant 
pertussis of routinely vaccinating all adolescents and adults critically depends on the 
proportion of infants infected by family members(19).  
Several studies have investigated the transmission of pertussis within households 
using a variety of study designs: case control studies in outbreak settings(20-22), investigations 
using general and hospital-based surveillance data(5, 23-25), and secondary analyses using 
vaccine efficacy trial data(26). These studies reported that parents (20-48%)(5, 23-25, 27) and 
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 siblings (19-53%)(5, 23-25) were common sources of infection for infants. However, 
interpretation of these findings is subject to important limitations. In these studies, the 
primary source of infection could not be identified in 47-60% of infant index cases. Further, 
except in one small study(27), the diagnosis of the index case was not always laboratory 
confirmed, and identification of source cases relied predominantly on a clinical diagnosis of 
pertussis. It remains therefore unclear who transmits pertussis to young infants.  
This study was designed to more precisely determine who transmits B. pertussis to 
young infants. We collected comprehensive clinical and biologic diagnostic data on close 
contacts to infant cases with laboratory confirmed pertussis.  
 
C. Methods 
 
Study setting and population 
A hospital based prospective study was conducted in France (4 hospitals), Germany 
(4 hospitals), the U.S. (3 hospitals), and Canada (1 hospital) from February 2003-September 
2004 (see list of participating hospitals of the Infant Pertussis Study Group). Data were 
analyzed at the University of North Carolina at Chapel Hill. Institutional Review Boards at 
each hospital and UNC approved the study. 
Three categories of participants were included in the study: infant index cases, 
household contacts, and close non-household contacts. Index cases were eligible if the infants 
were aged ≤6 months, unvaccinated or partially vaccinated (<3 doses) and diagnosed with 
laboratory confirmed pertussis (confirmed by culture or polymerase chain reaction [PCR]). 
Household contacts of the index cases were defined as persons living in the same residence 
as the infant index case during the month preceding pertussis diagnosis in the infant. Non-
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 household contacts were eligible if, during the month prior to symptom onset in the index 
case, they were either a full-time caretaker (>30 hours/week), or a person with an acute 
cough illness lasting ≥7 days. Potential participants were excluded if their residence was too 
distant for the family to attend for evaluation.  
Upon enrollment of the infant index case, data on age, gender, pertussis vaccination 
status, type and duration of pertussis symptoms, laboratory test results, family composition, 
and type of child care were collected. 
All household members of the index case were recruited upon informed consent and 
interviewed face-to-face using a standard questionnaire to obtain demographic and clinical 
data to identify potential non-household sources of pertussis. A respiratory sample 
(nasopharyngeal aspirate or swab) for culture and PCR detection of B. pertussis and a blood 
sample for IgG anti-pertussis toxin (anti-PT) antibody detection were collected. One month 
later, follow-up data on symptoms and a convalescent blood sample were collected. Potential 
non-household sources of infection were contacted by telephone, recruited, and followed the 
same study protocol as household contacts. 
 
Diagnostic laboratory procedures and quality control 
PCR and serum samples were sent frozen to the Reference Laboratory for Whooping 
Cough and other Bordetelloses, Institut Pasteur in Paris. PCR samples were analyzed by real-
time PCR using the IS481 target according to recommendations of the PCR pertussis 
consensus group(28). Serum samples were analyzed using a standardized enzyme-linked 
immunosorbent assay (ELISA) to quantify IgG anti-PT, as previously described(29), and using 
purified PT from sanofi pasteur. Assay cut-off was set at ≥ 20 EL U/ml.  
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 Case definitions 
Contacts were classified into one of four pertussis outcome categories: 1) laboratory 
confirmed symptomatic case, 2) epidemiologically linked symptomatic case, 3) laboratory 
confirmed asymptomatic infection, and 4) not infected. Outcomes were assigned using a case 
definition algorithm (Figure 1). Laboratory confirmed symptomatic cases reported symptoms 
of rhinorrhea or cough and met at least one of the following criteria: positive culture, positive 
PCR(28), a ≥ 4-fold change(30) in anti-PT IgG levels in paired serum samples, or a single anti-
PT IgG antibody titer ≥125 EU/mL(31-33). For immunized children aged 3 months through 2 
years, or 4 years through 7 years, single anti-PT titer results were not used for laboratory 
confirmation because recent vaccination may have influenced the IgG titers(8). 
Epidemiologically linked cases were persons in contact with the index case in the 
month preceding symptom onset in the index case and who had an acute cough illness lasting 
≥2 weeks, and had no laboratory confirmed pertussis(34). 
 Laboratory confirmed asymptomatic cases met the same criteria as laboratory 
confirmed cases, but did not report any cough or cold symptoms at either visit. Those 
classified as uninfected failed to meet any of the above criteria. 
A primary case was defined as a laboratory confirmed or epidemiologically-linked 
case with symptom onset between 7 and 30 days prior to symptom onset in the index case(25, 
35-39).  
 
Primary analysis 
 The primary analysis consisted of a complete case analysis in which only contacts 
with complete critical diagnostic information (i.e., PCR and serology) were included.  
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Sensitivity analyses investigating the effect of missing data 
In order to determine the impact of missing data on the study results two sensitivity 
analyses were conducted. In a highly conservative analysis, the strict complete enrollment 
analysis, the entire family was included only if every household member was enrolled and 
critical diagnostic results were available for every contact. In a less restrictive analysis, the 
all participant analysis, data on all participants were analyzed. When PCR and/or serology 
results were missing, pertussis outcome was assigned using the case definition algorithm 
(Figure 1). 
 
Sensitivity analyses investigating infants for whom a primary case was not identified 
Additional sensitivity analyses investigated why the primary analysis failed to 
identify a source case for some infants despite complete enrollment and diagnostic 
investigation. In the expanded primary case definition analysis, the timing of symptom onset 
to meet the primary case definition was expanded to 2-48 days prior to symptom onset in the 
index case. In the asymptomatic case analysis, contacts with asymptomatic laboratory 
confirmed infection were included as potential source cases(40) in families where no 
symptomatic primary case (using the expanded primary case definition) was identified.  
Data management and statistical analyses using Mantel-Haenzel Chi-square tests were 
conducted in SAS 9.1.3 (Cary, NC). 
D. Results 
 
Participants 
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 Ninety-five infant index cases (France=15, Germany=16, U.S.=62, Canada=2) and 
404 contacts (France=60, Germany=67, U.S.=269, Canada=8,) were enrolled. Of the eligible 
index cases and household contacts, 84.1% and 86.0%, respectively, participated. A mean of 
4.2 (range=1-13) contacts were enrolled per index case, and 29 (30.5%) of the index cases 
had at least one non-household contact enrolled. There were 206 adult household members 
(aged ≥18 years, except in the case of emancipated minors), 127 child household members 
(aged <18 years), and 71 non-household contacts enrolled. 
The mean age of the infant index cases was 2.9 months (range=0.53-6.9 months); 
70.5% were vaccinated at the appropriate age (i.e., had received the correct dose no later than 
30 days past the country specific scheduled date). Thirty-four (35.8%) infants had received 
one dose of pertussis vaccine and 8 (8.4%) had received two doses. Associations between age 
and number of received vaccine doses with being hospitalized are presented in Table 1. 
The distributions of collected diagnostic specimens for PCR and serology among 
close contacts to the infant index cases, contact level with the index case, and vaccination 
history stratified by type of contact are presented in Table 2. 
 
Primary analysis 
Among the 95 families enrolled, 3 had no contacts for whom complete data were 
available; 1 family had twin infant index cases with identical contact patterns and was 
analyzed as a single case. Of the remaining 91 (96.8%) unique families, 91 index cases and 
347 (85.9%) contacts had complete data. The prevalence of pertussis was 65.1% among all 
close contacts included in this analysis. The distribution of case-type is shown in Table 2. A 
source of infection was identified for 44 (48.4%) index cases. The majority (79.5%) of 
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 primary cases were laboratory confirmed. For 4 index cases, multiple primary cases were 
assigned as more than one laboratory confirmed primary case reported symptom onset on the 
same day. 
Among the 44 infants for whom a primary case was identified, household members 
were more often identified as primary cases than non-household contacts (75.5% vs. 24.5%). 
Parents accounted for 55.1% of the primary cases identified (18 mothers and 9 fathers), 
followed by siblings (16.3%), aunts/uncles (10.2%), friends/cousins (10.2%), grandparents 
(6.1%) and part-time caretakers (2.0%) (Table 3). Among the eight siblings identified as 
primary cases, four (two 3 year-olds, a 9 year-old and an 11 year-old) had a documented 
history of age appropriate pertussis immunization, one 15 year-old reported no previous 
vaccination, and three siblings (aged 4 years, 17 years, and 23 years) reported unknown 
vaccination status. 
Among the 47 (51.6%) index cases for whom no source case could be identified, 
complete enrollment and complete laboratory diagnostic tests for all household and eligible 
non-household contacts were available for 21 (44.7%), indicating potential transmission from 
a casual contact. For the remaining 26 families, there was at least one identifiable close 
contact who did not participate in the study, limiting our ability to draw conclusions 
regarding the source of infection for the infant. 
 
Sensitivity analyses investigating the effect of missing data 
In the conservative strict complete enrollment analysis 49 (52.1%) families were 
excluded due to missing data for one or more contacts. Among the 45 infants and 193 
contacts included in the analysis, a source case was identified for 62.2% of index cases. In 
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 the all participant analysis, all data for the 94 index cases and 404 contacts were included 
and a source case was identified for 53.2% of index cases. The differences in the distribution 
of relationships of the source cases in these sensitivity analyses and the primary analysis 
were small (0.2% to 5.1%), with overlapping 95% confidence intervals (Table 3). 
 
Sensitivity analyses investigating infants for whom a primary case was not identified 
 In the expanded primary case definition analysis, a primary case was identified for an 
additional 12 (13.2%) index cases. Seven primary cases had symptoms 31-48 days prior to 
onset in the index case, and 5 primary cases had symptoms 2-6 days prior to onset in the 
index case. A primary case was thus identified for 61.5% of all infants, as compared to 
48.4% in the primary analysis. The distribution of the relationships of the primary case to the 
index case remained similar (Table 3.) 
 When transmission from asymptomatically infected close contacts was assumed 
possible, a source case was identified for an additional 15 (16.5%) index cases, 6 of which 
were confirmed by serology only, 5 by PCR only, and 4 by both PCR and serology. In this 
sensitivity analysis, a primary case was identified for 71 (78.0%) index cases. Again, the 
distribution of relationships to the infant index cases remained similar to that in the primary 
analysis (Table 3).  
 
E. Discussion 
 
This study shows that parents (51-57%), siblings (17-22%), and non-household 
contacts (17-24%) are important sources of pertussis transmission to young infants. While 
these findings corroborate those from prior studies(5, 23-25, 27) (Table 4), they were robust to 
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 sensitivity analyses as evidenced by the relatively small range (<8%) in point estimates 
among each stratum of source cases. Additionally it had fewer limitations than previous 
studies. The prospective study design limited recall error in reporting the timing of symptom 
onset in contacts. The collection of biologic specimens (PCR and serology) on all household 
members, irrespective of symptoms, allowed laboratory confirmation of symptomatic cases 
and identification of asymptomatic infection. Inclusion of close non-household contacts 
allowed investigation of their role in pertussis transmission to young infants. Analysis of 
PCR and anti-PT ELISA at a reference laboratory avoided misclassification due to potential 
inter-laboratory variation in test performance. Further, the relatively large sample size 
allowed us to draw robust conclusions about who transmitted infection to young infants. 
Finally, in contrast to prior studies, we explored alternative hypotheses for index 
cases for whom no source could be identified. We evaluated the effect of missing data 
resulting from non-participation by household members, potential transmission from casual 
contact in the community, the effect of increasing the sensitivity of the definition for primary 
cases, and the potential role of individuals with asymptomatic laboratory confirmed infection 
in the transmission of pertussis to infants. We also expanded the period of infectiousness and 
reduced the incubation period based on data from Stocks(41), who used cough plates to 
determine the start and end of the infectious period among sequential cases within a 
household. In our study, we identified a substantial number of source cases with symptom 
onset 2-6 days and 31-48 days prior to onset in the index case. The finding that individuals 
with asymptomatic laboratory confirmed infection were the only pertussis cases among close 
contacts for 16.5% of index cases raises questions about the dogma that asymptomatic 
“carriers” do not transmit pertussis(42, 43).  
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 These results are important for evaluating the impact of current vaccination strategies 
and predicting the effect of new vaccination strategies on infant pertussis. The study 
corroborates the findings from Olin et al.(44) that infant vaccination protects against 
hospitalization. While it is vital to maintain high coverage rates and timely vaccination of 
infants and children against pertussis, we did not find that non-vaccination of siblings was a 
driving force for infant pertussis in this population. Although adolescents (aged 13-18) 
accounted for 16.3% of the primary cases identified (10% were non-household contacts and 
6% were siblings), their relative role in transmission may be greater since 66% of the infants 
did not have an adolescent contact. Routine adolescent vaccination may therefore not only 
have an important direct effect on adolescent pertussis, but will also likely play a role in 
combating infant pertussis. The impact of routine adult vaccination on infant pertussis will 
depend on the coverage rate among adults who come in close contact with young infants. 
In this population of young children, our study did not provide evidence for targeting 
non-household caretakers; indeed, their role was smaller than expected with only 1 (2.0%) 
part-time caretaker and no full-time caretakers identified as a source. Only 8 (8.5%) infants 
had a caretaker; therefore their relative role may be greater than the absolute 2% identified. It 
is possible some relatives played the role of caretaker, but they self-identified their 
relationship with the infant as relatives rather than caretakers. 
One study limitation is the inability to determine the temporality of infection between 
the index case and those asymptomatically infected. It is also possible some 
asymptomatically infected individuals failed to recall and report mild symptoms. Another 
limitation is we could not identify a source case in a substantial proportion of index cases in 
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 the primary analysis; however, a source case was identified in up to 78% of all index cases in 
sensitivity analyses. 
In conclusion, this study provides robust evidence that among infants where a source 
case can be identified (48-78%), household members are responsible for 73-82% of 
transmission of B. pertussis to infants, and mothers account for almost half. Both routine 
adult and adolescent vaccination and targeted booster vaccination of household members in 
close contact with infants have the potential to reduce a substantial proportion of the burden 
of infant pertussis if high coverage rates are achieved.  
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 Table 5.1. Associations of age and number of received vaccine doses with being hospitalized 
among infant index cases. 
  Hospitalized
Not 
Hospitalized  
    n % n % p 
Age      
 <2 months 32 42.7 3 15.0
 2-3 months 30 40.0 8 40.0
 4-6 months 13 17.3 9 45.0
0.015 
Number of vaccine 
doses      
 0 doses 46 61.3 7 35.0
 1 dose 27 36.0 7 35.0
  2 doses 2 2.7 6 30.0
<0.001
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 Table 5.2. Distribution of diagnostic specimens collected, amount of contact with the index 
case, vaccination history, and pertussis outcome status stratified by household category. 
Characteristic 
Adult 
Household 
Child 
Household 
Non-
household 
    n % n % n % 
Lab specimen collection       
 PCR 200 97.1 110 86.6 60 84.5
 Acute serology 201 97.6 93 73.2 60 84.5
 Convalescent serology 168 81.6 73 57.5 46 64.8
Close contact with index case       
 ≥ 5 hours/day 183 88.8 105 82.7 26 36.6
 1-5 hours/day 19 9.2 15 11.8 25 35.2
 <1 hours/day 3 1.5 5 3.9 19 26.8
 No close contact 1 0.5 2 1.6 1 1.4
Timing of Vaccination*        
 Infant (2-18 months) 127 61.7 113 90.4 47 66.2
 Child (4-6 years) 89 43.2 58 100.0 27 42.9
 Unknown** 45 21.8 3 2.4 14 19.7
Pertussis case classification†       
 
Lab Confirmed 
Symptomatic  73 37.2 40 42.6 23 40.4
 Epidemiologic-Linked 14 7.1 23 24.5 5 8.8
 
Lab Confirmed 
Asymptomatic 31 15.8 8 8.5 5 8.8
  No Infection (no case) 78 39.8 23 24.5 24 42.1
*Number and percent of persons vaccinated during infancy (2-18 months) and childhood (4-6 
years). Proportions were calculated among those old enough to be administered the specified 
dose 
**Persons reporting unknown vaccination for both doses were treated as not vaccinated. 
†Data from primary complete case analysis. Distributions from sensitivity analyses were 
similar (data not shown) 
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 Table 5.3. Proportion of infants for whom a primary case was identified and the distribution 
of primary cases according to relationship to the index case, age group, and household status, 
stratified by analysis type. 
  Primary Complete Case Complete Enrollment 
    N % 95% CI n % 95% CI 
Index Case      
 Included in analysis 91 100.0 (…) 45 100.0 (…) 
 
For whom a primary 
case identified 44 48.4 (37.7, 59.1) 28 62.2 (46.5, 76.2) 
       
Primary Case      
 Relationship      
 Parent 27† 55.1 (40.2, 69.3) 15 48.4 (30.2, 66.9) 
 Sibling 8 16.3 (7.3, 29.7) 5 16.1 (5.5, 33.7) 
 Aunt/Uncle 5 10.2 (3.4, 22.2) 4 12.9 (3.6, 29.8) 
 Friend/Cousin 5 10.2 (3.4, 22.2) 5 16.1 (5.5, 33.7) 
 Grandparent 3 6.1 (1.3, 16.9) 1 3.2 (0.1, 16.7) 
 Part-time caretaker 1 2.0 (0.5, 10.9) 1 3.2 (0.1, 16.7) 
        
 Age Group    
 Child <13 7 14.3 (5.9, 27.2) 5 16.1 (5.5, 33.7) 
 Adolescent 13-18 8 16.3 (7.3, 29.7) 7 22.6 (9.6, 41.1) 
 Adult 19-39 30 61.2 (46.2, 74.8) 17 54.8 (36.0, 72.7) 
 Adult 40-64 4 8.2 (2.3, 19.6) 2 6.5 (0.1, 21.4) 
 Adult 65+ 0 0.0 (…) 0 0.0 (…) 
     
 Household Type    
 Adult household 29 59.2 (44.2, 73.0) 17 54.8 (36.0, 72.7) 
 Child household 8 16.3 (7.3, 29.7) 5 16.1 (5.5, 33.7) 
 Adult non-household 7 14.3 (5.9, 27.2) 5 16.1 (5.5, 33.7) 
  Child non-household 5 10.2 (3.4, 22.2) 4 12.9 (3.6, 29.8) 
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 Table 5.3. Proportion of infants for whom a primary case was identified and the distribution 
of primary cases according to relationship to the index case, age group, and household status, 
stratified by analysis type. 
  
All Participant 
Expanded Primary 
Case Definition 
  n % 95% CI n % 95% CI 
Index Case       
 Included in analysis 94 100.0 (…) 91 100.0 (…) 
 
For whom a primary 
case identified 50 53.2 (42.6, 63.6) 56 61.5 (50.8, 71.6) 
        
Primary Case       
 Relationship   
 Parent 27 50.0 (36.1, 63.9) 33 54.1 (40.8, 66.9) 
 Sibling 11 20.4 (10.6, 33.5) 13 21.3 (11.7, 33.7) 
 Aunt/Uncle 6 11.1 (4.2, 22.6) 5 8.2 (2.7, 18.1) 
 Friend/Cousin 6 11.1 (4.2, 22.6) 6 9.8 (3.7, 20.2) 
 Grandparent 3 5.6 (1.2, 15.4) 3 4.9 (1.0, 13.7) 
 Part-time caretaker 1 1.9 (0.0, 9.9) 1 1.6 (0.0, 8.8) 
     
 Age Group    
 Child <13 11 20.4 (10.6, 33.5) 10 16.4 (8.2, 28.1) 
 Adolescent 13-18 9 16.7 (1.9, 29.3) 12 19.7 (10.6, 31.8) 
 Adult 19-39 29 53.7 (39.6, 67.4) 34 55.7 (42.4, 68.5) 
 Adult 40-64 5 9.3 (3.1, 20.3) 5 8.2 2.7, 18.1) 
 Adult 65+ 0 0.0 (…) 0 0.0 (…) 
     
 Household Type    
 Adult household 29 53.7 (39.6, 67.4) 34 55.7 (42.4, 68.5) 
 Child household 11 20.4 (10.6, 33.5) 14 23.0 (13.2, 35.5) 
 Adult non-household 8 14.8 (6.6, 27.1) 7 11.5 (4.7, 22.2) 
  Child non-household 6 11.1 (4.2, 22.6) 6 9.8 (3.7, 20.2) 
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 Table 5.3. Proportion of infants for whom a primary case was identified and the distribution 
of primary cases according to relationship to the index case, age group, and household status, 
stratified by analysis type. 
  Asymptomatic Case 
  n % 95% CI 
Index Case    
 Included in analysis 91 100.0 (…) 
 
For whom a primary 
case identified 71 78.0 (68.1, 86.0) 
     
Primary Case    
 Relationship 
 Parent 43 55.1 (43.4, 66.4)
 Sibling 16 20.5 (12.2, 31.2)
 Aunt/Uncle 6 7.7 (2.9, 16.0)
 Friend/Cousin 7 9.0 (3.7, 17.6)
 Grandparent 4 5.1 (1.4, 12.6)
 Part-time caretaker 2 2.6 (0.3, 9.0)
  
 Age Group 
 Child <13 12 15.4 (8.2, 25.3)
 Adolescent 13-18 16 20.5 (12.2, 31.2)
 Adult 19-39 43 55.1 (43.4, 66.4)
 Adult 40-64 6 7.7 (2.9, 16.0)
 Adult 65+ 1 1.3 (0.0, 6.9)
  
 Household Type 
 Adult household 47 60.3 (48.5, 71.2)
 Child household 17 21.8 (13.2, 32.6)
 Adult non-household 8 10.3 (4.5, 19.2)
  Child non-household 6 7.7 (2.9, 16.0)
†Mothers accounted for 18 and fathers accounted for 9 of these parents 
(…) – unable to calculate confidence intervals for proportions containing 0% and 100%.  
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Table 5.4. Comparison of studies estimating the source of infection to infants. 
 Renacoq 
200522 
Bisgard et 
al. 200419 
Crowcroft et 
al. 200318 
Halperin et 
al. 199920 
Wendelboe et 
al.2006 
No. of index cases 1519 616 33 1082 94 
Age range <6 mo <1 yr <5 mo <1 yr ≤ 6 mo 
% of index cases with identified source  53 43 42 40 48-78 
Source of pertussis      
  Parent (%) 56 47 42 20 48-55 
  Sibling (%) 23 20 NA 53 16-21 
  Non-household* (%) 19 26 NA 20 18-27 
Laboratory confirmation** in index case (%) 84 Some† 100 
  
Some† 100 
Diagnostic method in contacts      
  Symptoms Yes Yes Yes Yes Yes 
  Culture No No Yes Some‡ Yes 
  PCR No No Yes No Yes 
  Serology No No Some†† No Yes
Design type Prospective 
surveillance 
Retrospective 
surveillance 
Prospective 
case enrollment 
Retrospective 
surveillance 
Prospective case 
enrollment 
58
NA – Not available 
*Identifiable contacts among non-household members. 
**Laboratory confirmation included culture, polymerase chain reaction (PCR), and/or serology. 
†Data not available, but assumed that some proportion of diagnoses in index cases of pertussis were laboratory confirmed. 
††Single serology taken for adult contacts only, stored serum samples used for mothers where available. 
‡7.5% of contacts were verified by culture. 
Figure 5.1. Case definition algorithm for classification of pertussis outcome among contacts to laboratory confirmed infant index cases 
of pertussis. (Booster age range is defined as children aged 3 months through 2 years or 4 years through 6 years.) 
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 A. Abstract 
 
The amount of pertussis transmission due to casual contact in the community has not 
been estimated since the introduction of pertussis vaccines in the 1950s. This study aimed to 
estimate the amount of pertussis transmission due to casual contact using demographic and 
clinic data from a prospective study of 95 infant pertussis cases and their contacts enrolled at 
14 hospitals in France, Germany, Canada, and the U.S. from February 2003 to September 
2004. Data analyses utilizing complete case and multiple imputation (MI) analyses were 
conducted to account for missing data among non-participants and participants. The MI 
analysis identified a source case for 66% of the index cases, implying that casual contact 
from community members was responsible for 34% (95% CI=24%, 44%) of transmission to 
infants. Estimates from the complete case analysis were comparable but less precise. Results 
were sensitive to changes in sensitivity and specificity of the definition of a source case, 
which broadened the MI estimates of transmission from casual contact in the community to 
20%-48%. We conclude that casual contact appears to be responsible for a substantial 
proportion of pertussis transmission to young infants. 
B. Introduction 
 
Pertussis is the least well controlled bacterial vaccine-preventable disease in the U.S.1, 
2 Despite high immunization coverage rates (≈95% for the primary infant series3 and the 
booster at school entry4), the overall reported incidence in 2002 was 3.4/100,000 population, 
the highest incidence since 19645. Per 100,000 population, infants aged <6 months accounted 
for the greatest age specific incidence (108.8 cases) of pertussis, compared to 15.4 cases in 
infants aged 6 to 11 months, 8.9 cases in children aged 1 to 4 years, 4.8 cases in children 
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 aged 5 to 9 years, 7.0 cases in persons aged 10 to 19 years, and 1.2 cases among adults aged 
20 years and older5.  
Bordetella pertussis is reported to be among the most contagious pathogens in 
humans as an average of 15 secondary infections arise from a single case6. Nevertheless, 
public health messages often state that close contact is necessary for transmission1, 7, 8 
implying that pertussis transmission due to casual contact from community members is not 
appreciable. 
Several studies have investigated the disease dynamics of B. pertussis, especially as 
they relate to the transmission of the bacillus to young infants. These studies identified close 
contacts as the source of infection for 40-53% of young infants with pertussis9-12. None of 
these studies investigated whether the remaining 47-60% of transmission was due to casual 
contact in the community or transmission from close contacts not identified during the 
contact investigation. This is not surprising as there are several obstacles that hinder the 
estimation of the amount of pertussis transmission to young infants due to casual contact 
from the community. First, necessary data is often missing in transmission studies due to 
non-participation of close contact as well as missing information among participants. These 
missing data limit the ability to determine whether a given contact would have been 
identified as the source of the index case’s infection had the data not been missing. Second, 
diagnosing pertussis is often problematic since many adolescent and adult pertussis cases do 
not present with the typical symptoms of whooping cough13. This is further complicated by 
the lack of a highly sensitive and specific laboratory diagnostic method1, 14. Third, variability 
in the incubation and infectious periods15, 16 may result in failure to identify source cases if 
their incubation or infectious periods lie in the tails of the distributions not captured by 
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 standard definitions17-20. Finally, it is uncertain whether individuals with asymptomatic 
infection can transmit pertussis10, 21. Although according to convention the long-term carrier 
state does not exist15, 22, 23, cases of laboratory confirmed asymptomatic infection have been 
documented21, 22, 24. However, there is no known evidence regarding the infectiousness of 
those asymptomatically infected. Systematically excluding individuals with asymptomatic 
pertussis from being potential source cases may bias the results. 
Multiple imputation (MI) is a widely accepted method to account for missing data 
and is superior to complete case analyses for two reasons. First, as the amount of missing 
data increases, the results from complete case analyses suffer a greater loss in power than 
results obtained by MI analyses25, 26. Second, when data are not missing completely at 
random (MCAR) and the correct missing data mechanism is specified, MI  will produce 
unbiased estimates, whereas estimates from complete case analyses may be biased25, 27. 
In this study, we aimed to estimate the amount of pertussis transmission due to casual 
contact from the community. Data from a study designed to identify the source of infection in 
young infants were used and a complete case analysis was complemented with an MI 
analysis to account for missing data. In addition, sensitivity analyses were conducted to 
determine the effect of varying the sensitivity and specificity of the diagnostic methods and 
the source case definition, including an analysis allowing for transmission from individuals 
with asymptomatic infection. 
C. Methods 
 
Study design, participants, and data collection 
A prospective multi-center epidemiologic study was conducted in 14 hospitals in four 
countries: Canada, France, Germany, and the U.S. from February 3, 2003 through September 
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 15, 2004. Approval from Institutional Review Boards was obtained from each participating 
site. Partially vaccinated and unvaccinated infants aged ≤ 6 months diagnosed with 
laboratory confirmed pertussis (by Polymerase Chain Reaction [PCR] or culture) were 
invited to participate. Upon enrollment of the infant index case, all household members and 
eligible non-household contacts were recruited. Non-household contacts were eligible if they 
were in contact with the infant during the month prior to symptom onset in the index case 
and were either: 1) a full-time caretaker (>30 hours/week) of the infant index case or 2) had 
an acute cough illness lasting at least 7 days in the month prior to the pertussis diagnosis in 
the index case. 
Demographic and clinical information relevant to pertussis was collected on each 
index case. All contacts of the index case were interviewed face-to-face using a standard 
questionnaire to obtain relevant demographic and clinical data. During the interview with the 
parent of the index case, information was collected on all household members and eligible 
non-household contacts, independent of their participation in the study. Information collected 
pertained to the contacts’ relationship and amount of contact with the index case and the 
presence and duration of symptoms of cold or cough in the contact during the month prior to 
enrollment of the index case.  
All participants were asked to provide a sample collected via nasopharyngeal (NP) 
aspirate or swab for culture and PCR detection of B. pertussis and a blood sample for 
immunoglobulin-G (IgG) anti-pertussis toxin antibody (anti-PT) detection by enzyme-linked 
immunosorbent assay (ELISA). One month later, data on the presence of cough and cold-like 
symptoms and a convalescent blood sample were collected from all study participants.  
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 All PCR and serum samples were sent to the Reference Laboratory for Whooping 
Cough and other Bordetelloses Institut Pasteur in Paris. PCR samples were analyzed with 
Real-time PCR using the IS481 target. Any sample where Deoxyribonucleic Acid (DNA) 
was detected within 35 cycles was determined to be positive for B. pertussis28. Anti-PT IgG 
titers were determined by ELISA; assay cut-off was set at ≥ 20 EL U/ml. 
 
Case definitions 
Source cases were either laboratory confirmed or epidemiologically linked pertussis 
cases with onset of cough 2 to 48 days prior to symptom onset in the infant index case7, 16. 
When two or more contacts reported symptoms prior to the index case, the person with the 
earliest symptom onset (within the defined time-frame) was assigned as the source case. 
Multiple source cases were allowed if their symptom onset was reported to be the same day. 
Laboratory confirmation was defined by at least one of the following: positive culture, 
positive PCR, a ≥ 4-fold change29 in IgG titer to anti-PT between acute and convalescent 
serum samples, or a single anti-PT IgG antibody titer ≥ 125 EU/mL30, 31. For immunized 
children aged 3 months through 2 years and 4 years through 6 years, anti-PT titer results 
were not used for confirmation of pertussis as they may be influenced by recent vaccination. 
Epidemiologically linked cases were defined as persons in contact with the infant index case 
in the month preceding symptom onset in the index case, who had an acute cough illness 
lasting ≥ 2 weeks, but no laboratory confirmation of pertussis32. Laboratory confirmed 
asymptomatic cases of pertussis were also identified. They met the same criteria as 
laboratory confirmed symptomatic cases, but did not report any cough or cold symptoms.  
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 Missing data analyses: complete case and primary multiple imputation 
The complete case analysis included all index cases for whom (1) complete 
enrollment of all eligible close contacts (household and non-household) was achieved and (2) 
all enrolled contacts had complete diagnostic data, defined as information on symptoms, 
results from PCR, and results from at least one serum sample.  
MI was conducted in order to analyze the data on all index cases and their contacts, 
and thus increase the power of the study and the precision of the results. As some 
demographic and clinical data were available on all identified close contacts, independent of 
study participation, missing data on non-participants could be treated the same as participants 
with missing diagnostic data. This information was used as predictor variables in building the 
imputation model. The imputation model utilized logistic regression to predict the probability 
that each contact with missing data was the source case for the index case  (Y=1 if a source 
case, Y=0 if not a source case), adapting the methods described by Raghunathan et al.27 for 
non-sequential logistic regression. Profiles incorporating a combination of the explanatory 
variables listed above were generated using indicator variables. For example, a parent with a 
cough lasting ≥ 2 weeks and contact with the index case for >5 hours/day was one profile 
(X1), a sibling with a cough lasting ≥ 2 weeks and contact with the index case for >5 
hours/day was another profile (X2). Household size (a count variable) was also included in 
the predictive model.  
To account for uncertainty introduced by using maximum likelihood estimates 
(MLEs) in lieu of the true parameter values in the missing data model, random error was 
added to the MLEs when creating each of 10 imputed datasets. This was accomplished by 
adding the product of the Cholesky decomposition of the covariance matrix and a random 
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 normal deviate to the MLEs27. A uniform random number (0, 1) was sampled for each 
individual with missing data and compared to each individual's predicted probability of being 
a case. A value of Y=1 was imputed if the uniform random number was less than or equal to 
the predicted probability; otherwise a value of Y=0 was imputed33. 
The missing data mechanism was assumed to be ignorable. This assumption cannot 
be explicitly verified with the available data because the response variable (source case 
status) is not observed among those with missing data34. An ignorable missing data 
mechanism in this study means that missingness (i.e., failure to enroll or provide diagnostic 
specimens) was independent of being a source case, conditional on the observed data (age 
and household status). 
 
Sensitivity analyses  
Sensitivity analyses were conducted on the multiply imputed data to assess the impact 
of the sensitivity and specificity of the source case definition. In the specific source case 
definition analysis, specificity was increased by requiring symptom onset in the source case 
to occur 7 to 30 days prior to symptom onset in the index case17-19, 35, 36. In the sensitive 
source case definition analysis, sensitivity was increased by allowing individuals with 
laboratory confirmed asymptomatic pertussis to be source cases when no other source case 
could be identified for an infant index cases. In this analysis, the outcome value (source case 
status) was imputed using MI for all persons with missing data, independent of symptoms. 
 
Estimate computation and regression analyses 
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 Multiply imputed data were analyzed and standard errors accounting for MI34 were 
calculated in SAS 9.3.1 (Cary, NC).  General estimating equation (GEE) regression was 
conducted since possible clustering within households likely violated the independence 
assumption. In order to overcome non-convergence problems using binomial regression, 
modified poisson regression was used to estimate the log binomial model37. Models were fit 
to the multiply imputed data using forward entry to calculate risk ratios and 95% confidence 
intervals (95% CI) to identify risk factors associated with the probability of not identifying a 
source case among the index cases.  
 
D. Results 
 
Participants 
The study population comprised 95 infant index cases and 404 contacts. A pair of 
twins were enrolled and treated as a single case. Of all eligible close contacts, 88% 
participated. Had all of the eligible household members and the two identified eligible non-
household contacts enrolled in the study, there would have been a total of 460 close contacts. 
For the complete case analysis, complete enrollment of the household was achieved and 
complete diagnostic data were collected for 45 (47.9%) index cases and their 193 (47.8%) 
contacts. However, for the primary MI analysis, the dichotomous outcome value of being a 
source case was missing for 44 (9.6%) symptomatic contacts and 105 (22.8%) contacts in the 
sensitivity analysis allowing those with asymptomatic infection to be source cases (Table 
6.1). 
The distribution of missing diagnostic specimens stratified by household status (adult 
household, child household and non-household status) is presented in Table 1. Among 
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 participants, child household contacts and non-household contacts were more likely than 
adult household contacts to be missing diagnostic specimens (OR= 6.9 (95% CI=3.3, 14.6) 
and OR= 4.8 (95% CI=2.0, 11.4), respectively). This demonstrates that the data were not 
missing completely at random. Non-participation was not associated with age (OR=1.0, 95% 
CI=0.98, 1.01), symptoms before the first visit (OR=0.7, 95% CI=0.4, 1.2), or level of 
contact with the infant (OR=1.0, 95% CI=1.0, 1.1). Siblings (OR=2.5, 95% CI=1.1, 5.4) and 
“other” contacts (OR=3.3, 95% CI=1.6, 7.0) were less likely than parents to enroll.  
 
Complete case and multiple imputation analyses 
 The proportion of infants for whom a source could not be identified was similar 
between the MI (33.9%, 95% CI=23.6%, 44.3%) and complete case analyses (31.1%, 95% 
CI=17.6%, 44.6%), but the estimate from the MI analysis was slightly more precise (Table 
6.2). Assuming partially classified observations were missing at random and no 
misclassification of outcome status resulted due to the diagnostic method, it can be inferred 
that casual contact from the community was responsible for those infants for whom no source 
case was identified. Accounting for clustering within households using GEE methods did not 
substantially affect the results.  
 
Sensitivity analyses 
 In the specific source case definition analysis, using the more restrictive and specific 
period of incubation and infectiousness (7 to 30 days), a source case was identified for an 
average of 49 (52.3%) index cases (range 47 to 52), implying that casual contact in the 
community was responsible for 47.7% (95% CI=37.1%, 58.3%) of transmission to young 
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 infants (Table 6.2). In the sensitive source case definition analysis, allowing laboratory 
confirmed asymptomatically infected persons to be source cases, a source case for an average 
of 75 (79.8%) infants (range 73 to 77) was identified, implying the remaining 20.2% (95% 
CI=11.7%, 28.8%) of index cases were infected by casual contact in the community (Table 
6.2). 
 
Predictors of transmission from the community  
 Risk ratios (95% confidence intervals) for characteristics of the index cases 
associated with an unidentified source of transmission, implying transmission from casual 
contact in the community, are presented in Table 6.3. Time from symptom onset to diagnosis, 
childcare outside the home, and household size were factors we a priori thought might be 
associated with community transmission. None of the characteristics were associated in crude 
or fully adjusted analyses. However, continent of residence showed the strongest association 
(RR=3.29; 95% CI=0.86, 12.67). 
 
E. Discussion 
 
This is the first study in the vaccine era to estimate the amount of pertussis 
transmission to young infants due to casual contact from community members. We were able 
to provide a relatively precise estimate of casual transmission by complementing the 
complete case analysis with an MI analysis to account for missing data. Specifically, by 
collecting some data on all non-enrolled eligible close contacts (during the first interview 
with the parents of the infant index case) we could build an imputation model allowing for 
the analysis of 94 index cases and their 460 contacts. Consequently, we were able to infer 
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 that in the absence of identifying a source case among close contacts of the index infant 
cases, pertussis transmission to these young infants was due to casual contact in the 
community. In the primary complete case and MI analyses, we found that casual community 
contact was responsible for 31.1% (95% CI=17.6%, 44.6%) and 33.9% (95% CI=23.6%, 
44.3%), respectively, of pertussis transmission to young infants. These results were sensitive 
to changes in the source case definition. When the more specific source case definition 
requiring symptom onset in source cases to occur 7 to 30 days prior to symptom onset in the 
index case was used, the estimated amount of transmission due to casual contact increased to 
47.7% (95% CI=37.1%, 58.3%). Allowing persons asymptomatically infected with pertussis 
to be source cases in the absence of identifying a symptomatic source case resulted in 
reducing the estimate of transmission due to casual contact to 20.2% (95% CI=11.7%, 
28.8%). 
The only other study to estimate the proportion of casual or community transmission 
was performed in the pre-vaccine era. In 1913-1914, Luttinger followed 2,310 pertussis cases 
who attended a whooping cough clinic38. The sources of infection, as reported by the 
guardian, were: neighbor (56.8%), relative or friend (17.6%), school or nursery (9.6%), 
movies, recreation pier, roof gardens, ferry, street, and public transportation (4.6%) and 
unknown (11.4%). Thus, depending on the definition of “the community,” exposure from 
casual community contact accounted for 4.6% to 16.0% (including movies, etc., and 
unknown) of transmission38. Considering the dramatic change widespread vaccination 
wrought on the epidemiology of pertussis39, the comparison of results is somewhat trivial. 
However, one explanation for the observed increase in transmission due to casual contact is 
that due to the >99% reduction in pertussis incidence following widespread vaccination39, the 
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 probability of knowing somebody with pertussis is much lower today than in the pre-vaccine 
era; thus making the identification of the source case more difficult. Additionally, since in the 
vaccine era the presentation of pertussis in often atypical and mild, pertussis is often not 
considered for diagnosis40. 
This study attempted to overcome several obstacles in identifying the amount of 
pertussis transmission to young infants due to casual community contact. In addition to 
addressing missing data and accounting for variability in the incubation and infectious 
periods of source cases, we also questioned whether asymptomatically infected individuals 
could transmit infection. It is generally believed that transmission from individuals with 
asymptomatic infection does not occur since they do not cough or sneeze and thus do not 
generate the infectious aerosol droplets necessary for efficient spread41. Although including 
asymptomatic carriers as potential source cases may result in misclassification and thus 
overestimate of the effect of transmission from casual contact, systematically excluding them 
as source cases may underestimate the effect. Asymptomatic infection has been previously 
documented21, 22, 24 and in the context of infant pertussis where respiratory secretions may be 
shared through activities such as kissing, cuddling, and singing, it is plausible that 
transmission may occur from asymptomatic carriers. The finding that a source case was 
identified for an additional14% of infants in the sensitivity analysis allowing those 
asymptomatically infected to be source cases underscores the potential role of these carriers 
in the transmission of B. pertussis to young infants. However, this analysis is limited by the 
unknown chronology of infection as those with asymptomatic infection could have been 
infected by the index case. 
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 When analyzing index case characteristics that could potentially be associated with 
the source of transmission, we failed to identify factors significantly associated with 
transmission due to casual contact from the community. Similar to our results, a study in 
1988 attempted to identify risk factors for community-acquired pertussis, but found that 
exposure outside the household was the only significant predictor42. 
An important limitation of all analyses with missing data that cannot be overcome by 
any analytical method, including MI, is the inability to prove the missing data mechanism 
was ignorable (i.e., missingness was not dependent on source case status given the observed 
data). For simplicity we assumed an ignorable missing data mechanism. To assess the 
validity of this assumption we used symptoms as a proxy measure for being a source case (as 
it is a prerequisite for being a source case in the main analysis) and found that participants 
with missing data and non-participants were less likely to be symptomatic than participants 
with complete data (OR=0.69 (95% CI=0.39, 1.20) and OR=0.70 (95% CI=0.40, 1.22), 
respectively). We interpret this to suggest that the missing data mechanism was ignorable. 
However, if source cases were more likely to be enrolled than non-source cases, the results 
would not be biased due to systematic non-enrollment of source cases. Ideally a validation 
study should be conducted to determine the nature of the missing data mechanism, thus 
allowing the empirical specification of the model for the missing data mechanism25. 
In conclusion, this study presents evidence that casual contact from the community is 
responsible for 20-48% (including confidence intervals (11%-59%)) of pertussis transmission 
to young infants. This proportion is higher than the report from the pre-vaccine era and may 
be due to the atypical presentation of pertussis and a strikingly lower incidence of pertussis in 
the vaccine era. In an effort to better control pertussis incidence, the U.S. Advisory 
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 Committee on Immunization Practices (ACIP) recommended in 2006 that all adolescents and 
adults receive a booster dose of Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular 
pertussis vaccine) in place of Td (tetanus and diphtheria toxoids vaccine)1. Understanding 
who infects young infants with B. pertussis, including the proportion due to casual 
community contact, will be important in evaluating the effectiveness of the new adolescent 
and adult vaccination strategies on the control of infant pertussis. 
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Table 6.1. Distribution of missing enrollment, missing diagnostic specimens and missing outcome status by household status. 
*Two non-household contacts with confirmed pertussis and symptom onset prior to the infant were identified as the most probable 
source cases for the associated infant. Therefore, outcome status was not missing even though they were not enrolled. 
Adult 
Household 
Child 
Household 
Non-household 
Total 
Characteristics associated with missingness of data 
among contacts  
  n % n % n % n % 
Identified contacts 236 100.0 151 100.0 73 100.0 460 100.0 
     Enrolled  206 87.3 127 84.1 71 97.3 404 87.8 
     Not enrolled 30 12.7 24 15.9 2 2.7 56 12.2 
     Symptomatic 107 45.3 89 58.9 46 63.0 242 52.6 
     Asymptomatic 129 54.7 62 41.1 27 37.0 218 47.4 
Contacts with missing outcome (source case) status due 
to missing data 
      
 
 
 Symptomatic contacts missing outcome status 12 5.1 26 17.2 6 8.2 44 9.6 
 PCR and Serology missing 1 0.4 9 6.0 5 6.8 15 3.3 
 PCR missing and negative serology 0 0.0 0 0.0 0 0.0 0 0.0 
 Serology missing and negative PCR 0 0.0 5 3.3 1 1.4 6 1.3 
 Not enrolled 11 4.7 12 7.9 2* 2.7 25 5.4 
 Asymptomatic contacts missing outcome status         
 Asymptomatic** 25 10.6 29 19.2 7 9.6 61 13.3 
 PCR and Serology 2 0.8 8 5.3 5 6.8 15 3.3 
 PCR and negative serology 4 1.7 0 0.0 0 0.0 4 0.9 
 Serology and negative PCR 0 0.0 9 6.0 2 2.7 11 2.4 
 Not enrolled 19 8.1 12 7.9 0 0.0 31 6.7 
 All contacts with missing outcome status 37 15.7 55 36.4 13 17.8 105 22.8 
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**Multiple Imputation was not used to impute source case status among asymptomatic persons in the main analysis (and the specific 
case definition analysis), because they are by definition on not a source case in these analysis.  
Table 6.2. Proportion of infants for whom a source case was identified and for whom casual community contact was likely 
responsible, stratified by analysis type. 
Infants included 
in analysis 
For whom a source case was 
identified 
For whom contact in 
community likely responsible 
Analysis 
n % n % 95% CI  n % 95% CI
Complete Case  45 47.9 31 68.9 (55.4, 82.4) 14 31.1 (17.6, 44.6)
Primary MI  94 100.0 62 66.1 (55.7, 
   
 
76.4) 32 33.9 (23.6, 44.3) 
Specific Source Case Definition* 94 100.0 49 52.3 (41.7, 62.9) 45 47.7 (37.1, 58.3)
Sensitive Source Case Definition** 94 100.0 75 79.8 (71.2, 88.3) 19 20.2 (11.7, 28.8)
*The specific primary case definition analysis requires symptom onset in primary cases to occur 7-30 days prior to symptom onset in 
the index case.  
**The sensitive primary case definition allows asymptomatically infected persons to be primary cases in the absence of identifying a 
symptomatic primary case. 
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 Table 6.3. Characteristics of the infant index case analyzed to determine potential 
associations with not identifying a source case for infant cases of pertussis. 
 Crude Fully Adjusted 
Characteristic of infant index 
case RR 95% CI RR 95% CI 
Time to diagnosis       
  <13 days 1.00 (…) 1.00 (…) 
  14-20 days 1.53 (0.64, 3.67) 1.22 (0.45, 3.31) 
  21-27 days 0.59 (0.13, 2.69) 0.49 (0.10, 2.54) 
  28+ days 1.92 (0.65, 5.69) 1.60 (0.40, 6.36) 
Age       
  <2 months 0.75 (0.28, 1.98) 0.52 (0.08, 3.31) 
  2-3 months 0.98 (0.39, 2.47) 1.33 (0.43, 4.16) 
  4-6 months 1.00 (…) 1.00 (…) 
Male gender 1.10 (0.52, 2.29) 1.20 (0.55, 2.60) 
Vaccinated 1.57 (0.74, 3.31) 0.59 (0.13, 2.69) 
Household size 1.03 (0.87, 1.23) 1.07 (0.85, 1.33) 
Non-houshold contact enrolled 0.93 (0.42, 2.04) 1.04 (0.41, 2.62) 
Childcare outside the home 1.57 (0.48, 5.20) 1.68 (0.39, 7.18) 
Adolescent in close contact 0.70 (0.31, 1.59) 0.45 (0.14, 1.40) 
Hospitalized 0.55 (0.25, 1.10) 0.87 (0.30, 2.52) 
Continent of residence      
  Europe 1.00 (…) 1.00 (…) 
  North America 2.59 (0.91, 7.36) 3.29 (0.86, 12.67) 
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 A. Summary 
 
Accurately diagnosing pertussis disease is a challenge. The widespread use of 
pertussis vaccines has dramatically changed the epidemiology of pertussis such that many 
pertussis cases do not present with the hallmark symptom, inspiratory whoop. A variety of 
laboratory tools are available to aid in the diagnosis of pertussis, specifically culture, direct 
fluorescent antibody (DFA) testing, polymerase chain reaction (PCR),  and paired and single 
serology techniques. This article reviews the strengths and limitations (including the 
sensitivity and specificity) of each of these diagnostic tools.  
B. Introduction 
 
Accurately diagnosing pertussis disease is a challenge. In the pre-vaccine era, the 
majority of cases occurred in pre-school and young elementary school aged children1 and 
many cases presented with the classic pertussis symptoms: paroxysmal cough, inspiratory 
whoop and post-tussive vomiting. Currently, after more than 5 decades of the widespread use 
of the pertussis vaccine, the majority of cases occurs in young infants and previously 
vaccinated adolescents and adults. In these populations the classic pertussis symptoms are 
usually absent. Pertussis in young infants is often severe, frequently resulting in 
hospitalization and even death2. In contrast, disease in previously vaccinated adolescents and 
adults is usually milder, presenting with prolonged cough but without inspiratory whoop, 
paroxysmal coughing, and post-tussive vomiting3. Diagnosing pertussis in the vaccine era 
requires knowledge of the epidemiology, the clinical picture of pertussis according to 
vaccination status and age, and the sensitivity and specificity of available laboratory tests. 
This article provides a historic review of the developments in laboratory diagnosis of 
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 pertussis, highlights the recent developments and the advantages, disadvantages, sensitivity 
and specificity of the current state of the art pertussis diagnostics.  
C. Clinical diagnosis 
 
Pertussis (also known as whooping cough) is an infection of the respiratory tract 
caused by Bordetella pertussis. The infection is characterized by 4 stages: incubation, 
catarrhal, paroxysmal, and convalescence. The asymptomatic incubation period typically 
lasts about one week (range 5-21 days)4-6. The catarrhal stage, which is the most infectious 
stage, lasts one to two weeks and is characterized by symptoms similar to mild upper 
respiratory tract infections such as rhinorrhea, low-grade fever, and mild non-productive 
cough. Pertussis is seldom included in the differential diagnosis at this stage, except in the 
context of pertussis outbreaks or if there was known exposure to a confirmed pertussis case. 
The paroxysmal stage, the hallmark of pertussis, typically persists for 2-3 weeks but can last 
as long as 10 weeks and is characterized by a more severe paroxysmal cough, often 
accompanied by an inspiratory high-pitched whoop. Gagging, gasping, and expectoration of 
thick mucous are also common. It is during this stage that individuals presenting with these 
characteristic pertussis symptoms are often clinically suspected of pertussis. In the final 
convalescent stage, lasting 2-3 weeks, the cough becomes less severe and recovery is 
gradual5. Presently (in the vaccine era), the majority (up to 67%) of pertussis cases are 
subclinical7-9, Even when children present with a cough of two weeks or more, physicians 
only considered pertussis in 25% of cases10.  Infants, the population group that comprises the 
highest proportion of cases by age (e.g., 24% in the United States11) and accounts for the vast 
majority of hospitalizations, serious complications, and morbidity2, 12, 13 generally have 
severe disease but have atypical presentations and lack the characteristic whoop2, 14, 15. 
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 Adults, adolescents and older children often have milder presentations16-18. In one study only 
6% of 95 pertussis patients aged 5 to 30 years presented with whoop and in another, 26% of 
culture confirmed cases had cough less than 21 days19.  
A standard clinical case definition has been developed for surveillance purposes by 
the World Health Organization (WHO) and the Centers for Disease Control and Prevention 
(CDC). In the absence of an epidemiologic link to a known pertussis case a case of clinical 
pertussis is defined as a person with a cough lasting at least two weeks and accompanied by 
at least one of the following symptoms: paroxysms of coughing, inspiratory whoop, or post-
tussive vomiting without other apparent cause20, 21. 
The specificity and sensitivity of this definition in clinical settings outside of 
outbreaks has not been thoroughly evaluated. In two studies investigating outbreak settings, 
the presence of a cough for at least two weeks with paroxysms of coughing, inspiratory 
whoop, or post-tussive vomiting  had a sensitivity of 67 – 89% and specificity of 52 – 94%22, 
23.  
The CDC case definition in outbreaks settings, when the contact is epidemiologically 
linked to a confirmed case, does not require the additional symptoms of paroxysmal cough, 
inspiritory whoop, or post-tussive vomiting20. While not requiring the more severe symptoms 
likely increases the case definition’s sensitivity, a proportion of mild, atypical  cases and all 
asymptomatic infections will still be missed, limiting the sensitivity of this definition9. 
Again, no comprehensive study on the specificity and sensitivity of this definition has been 
undertaken. Considering the difficulties associated with the clinical diagnosis of pertussis, it 
is strongly recommended that laboratory confirmation should be sought when possible24. 
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 D. Culture 
 
Isolation of Bordetella pertussis through culture is the imperfect, though traditional, 
“gold standard” for diagnosing pertussis. The method to culture B. pertussis was developed 
in 1906 by Bordet and Gengou25, and entails the collection and plating of biologic specimens 
on either charcoal agar with horse blood26 or Bordet-Gengou agar27. Often, culture medium is 
supplemented with cephalexin to inhibit the growth of competing flora, improving selection 
for B. pertussis28. When transport medium is used, either Regan-Lowe medium28 or charcoal 
containing Amies medium29 should be used.  Plates should then be incubated at 36°C for a 
mean of 5 days30, 31 (though growth may take more than 7 days32). The relatively long culture 
time is a drawback to using culture in the clinical and outbreak setting. Experience and 
expertise in both sampling and culture technique are required to prevent false negative 
results. Nasopharyngeal aspirates are typically more reliable than nasopharyngeal swabs33. 
Unfortunately, because the technique of obtaining nasopharyngeal aspirates is more difficult, 
swabs are frequently used to collect the respiratory specimen. When swabs are taken, it is 
important to use calcium alginate or Dacron swabs as cotton inhibits the growth of B. 
pertussis31.  
Culture has traditionally been used as the gold standard because it is nearly 100% 
specific34; however it’s sensitivity is poor, ranging from 12-60%30, 35-39 . The sensitivity is 
influenced by the following factors. First, the ability to culture B. pertussis is optimal at the 
first onset of symptoms, i.e., during the catarrhal stage. Culture may be up to 80% sensitive 
when collecting specimens within the first two weeks of cough onset among patients who 
persist to cough for more than  four weeks,19 but decreases over time and becomes relatively 
poor by the onset of paroxysms30, 40, the time at which pertussis is typically suspected. 
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 Second, the younger age of the patient can decrease the ability to successfully culture the 
organism30.  
Some advantages unique to culture allows to test for antibiotic resistance41, 
differentiate between different B. pertussis strains by molecular epidemiological analysis31, 
and differentiate between different B. pertussis species31. When cultured, both B. pertussis 
and B. parapertussis share similar morphology, but B. pertussis is oxidase positive whereas 
B. parapertussis is oxidase negative19 and does not secrete pertussis toxin42. While it is 
generally held that symptoms caused by B. parapertussis infection are similar but less severe 
than those caused by B. pertussis infection43, 44, two recent studies found no difference45, 46. 
B. parapertussis is also reported to be less transmissible and is diagnosed less frequently than 
B. pertussis.43, 45 It is however possible that some proportion of all diagnosed pertussis is due 
to B. parapertussis infection46.  
In conclusion, while a positive culture is solid evidence of B. pertussis infection, 
failure to culture B. pertussis from a respiratory specimen does not exclude a diagnosis of 
pertussis. Furthermore, the low sensitivity of culture makes the evaluation of other tests’ 
specificity against this “gold standard” problematic. 
E. Direct Fluorescent Antibody (DFA) 
 
Prior to the development of PCR in the 1990s, direct fluorescent antibody (DFA), 
developed in the 1960s, was the most rapid test available to diagnose pertussis47. A positive 
diagnosis is made by directly observing the isolation of B. pertussis. DFA has poor 
sensitivity (ranging between 11-68.%48-53) and high specificity of 99.6-100%50, 52, 53, but 
specificity has been reported to be as low as 12%51.  
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 F. Polymerase Chain Reaction (PCR) 
 
Since the 1990’s polymerase chain reaction (PCR) has gained popularity as a 
diagnostic tool, both in clinical and research settings. The first peer reviewed article 
documenting its use to detect B. pertussis was in 1989 by Houard et al.54 Since then, 
numerous PCR methods have been described39, 55-57. By 1992-1993, its routine use in the 
clinical setting has been promoted58, 59. In 1994 the first international standardized criteria of 
the PCR method for pertussis were published60. In 2005, new revised recommendations were 
made by the pertussis consensus group. The new standard procedure recommends the  use of 
nasopharyngeal aspirate or Dacron swabs, commercialized kits for deoxyribonucleic acid 
(DNA) extraction, controls for DNA extraction, an internal control for detecting inhibitors, 
and an external control for identifying contamination61. However, currently no method or kit 
has been approved by the U.S. Food and Drug Administration. 
Two primary primers have been frequently used to target specific gene sequences of 
B. pertussis: insertion sequence IS48159, 62 and pertussis toxin (ptxA-Pr) promoter region40, 54. 
The IS481 target is reported to have the highest diagnostic sensitivity61, but cross reacts with 
B. parapertussis and B. holmesii, reducing specificity63. In clinical settings, cross-reactivity 
with B. holmesii has little impact on reducing the specificity of the IS481 target since 
infection with B. holmesii is rare63, 64. To rule out infection with B. parapertussis the unique 
insertion sequence IS100165 may be used in a duplex method with IS48156, 66. The ptxA-Pr is 
unique to B. pertussis, and a real-time PCR method approaches 100% specificity61. 
Sensitivity of the ptxA-Pr primer is consistently lower than for IS48161, 67. Two additional 
targets have been used to a lesser extent to diagnose pertussis, the adenylate cyclase gene68 
and the porin gene69; however most of the current PCR debate is focused on the choice 
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 between the IS481 and the ptxA-Pr as the standard target. Consistently using both targets 
would be too costly61. 
PCR has three main advantages compared to culture. First, it is a highly sensitive 
diagnostic method, usually twofold that of culture, with studies reporting sensitivities ranging 
from 70 – 99%30, 36, 37, 39, 62, 63, 70 in a population with the same characteristics56, 71, 72. Second, 
while sensitivity decreases with time since infection63, PCR can detect B. pertussis infection 
later in disease progression compared to culture73, especially in younger children and 
infants63 Third, PCR results can be available in as few as two hours56,  as opposed to 5 to 10 
days for culture, 30, 31 which is especially valuable in clinical and outbreak investigation 
settings. 
The principle limitation of PCR in comparison to culture is its lower specificity, 
especially when using the IS481 target. A relatively wide range (86% to 100%) of 
specificities have been reported30, 38, 39, 56, 57, 74, 75.  While most of the decreased specificity is 
due to cross-reactivity with other Bordetella species, laboratory contamination is also of 
greater concern with PCR than with culture76. However, the use of inhibitory controls and 
closed systems limit the impact of contimation57. Another limitation is that PCR has been 
reported to be costlier than culture77. When PCR assays are run in batches, the cost decreases 
to approximately that of culture,48 but turn over time is also increased. 
In conclusion, the move towards international standardization of the PCR technique 
will substantially improve our capability to diagnose pertussis and may eventually replace 
culture as the gold standard. Currently, despite the substantially greater sensitivity, 
comparable specificity, and faster time to results of PCR compared to culture, there is still 
resistance to make PCR the gold standard in diagnosing pertussis25, 78. The high specificity of 
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 a positive PCR result provides strong evidence of B. pertussis infection and disease. 
However, similar to culture, a negative PCR result does not provide conclusive evidence 
against pertussis disease7, 79, 80, especially if the respiratory sample is collected a few weeks 
or more after the onset of symptoms. 
G. Serology 
 
Serological methods have been used to diagnose pertussis for nearly a century. In 
1911, Bordet and Gengou published the first serological methods, detecting agglutinating 
antibody to whole B pertussis cells81.  Since the 1980s, enzyme-linked immunosorbent assay 
(ELISA) has replaced the measurement of agglutinating-antibody as the principle method to 
diagnose pertussis. Infection with B. pertussis elicits an immune response to a number of 
antigens, including filamentous hemagglutinin (FHA), pertactin, fimbrae (types 2 and 3), and 
pertussis toxin (PT)82 (also known as lymphocytosis promoting factor). Only antibodies to 
PT (IgG-PT) are specific to B. pertussis42 as antibodies to the other antigens cross-react with 
other Bordetella and non-Bordetella species81, 83, 84. IgG-PT appear relatively late in the 
course of infection, as late as 3 weeks after the start of illness, and reaches its peak 
approximately 4.5 weeks after infection25. 
PT, FHA, pertactin, and fimbrae are antigens present in the whole cell and in most 
acellular pertussis vaccines which elicit an IgG humoral response. Current methods are not 
capable of distinguishing whether the source of IgG antibodies in recently vaccinated 
children are from natural infection or vaccination. Immunization probably does not elicit an 
IgA response in previously non-infected persons85-89, and there is evidence of low titers of 
anti-PT and anti-FHA IgA in the general population90. There is however, little experience 
using IgA serology as a diagnostic tool for pertussis. 
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 Currently, a variety of serological methods are being used in the diagnosis of 
pertussis, including an array of antigens (PT, FHA, and fimbriae), and the use of both paired 
and single serology techniques. Furthermore, different diagnostic criteria are used, including 
(but not limited to) four-fold and two-fold changes in paired antibody titers and a cut-off of 
100 to 125 ELISA Units/mL using single serum methods. As a result, a range of sensitivities 
(33.3%-92%49, 70, 91, 92) and specificities (72%-100%70, 93-95) have been reported. Below is a 
detailed discussion of both paired and single serology methods. 
 
1. Paired serology 
 
Until recently, the standard method for serological diagnosis of pertussis has been the 
analysis of paired (i.e., acute and convalescent) sera. When collected properly (and not 
confounded by recent vaccination), a substantial rise in antibody titer is a highly specific 
measure of infection81. The accurate interpretation of this method relies upon correctly 
timing the collection of both samples. The first sample should be drawn during the acute 
phase of the disease (i.e., soon after infection, when the host has not yet mounted an antibody 
response), and the second sample should be drawn 4 to 6 weeks later, during the 
convalescent stage when the antibody response is near its peak. Collecting the acute sample 
early in infection is particularly difficult because of frequent late recognition of the disease. 
If the “acute” sample is drawn too late in infection, the immune response will likely result in 
a high antibody titer and consequently not allow the detection of a significant (2 or 4 fold) 
rise by the time the convalescent serum is collected. Due to these restrictive conditions, the 
use of paired serum methods has not been useful in clinical settings. 
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 Several criteria have been used to interpret a change in antibody titers from paired 
sera, including two23, 92, 96-98, three35, and four-fold8, 63, 90, 94, 99 rises in titer and raises in titer 
beyond the 99th percentile from control titer distributions72, 83. The primary argument for 
using a four-fold rise in titer instead of a two or three-fold rise in titer is because results are 
less susceptible to interference from intra-assay variation35, 81 (which could decrease the 
specificity). Those that have used the less stringent criteria have argued low intra-assay 
variation96, 98 or established a minimum absolute titer value which required a significant rise 
in titer to be greater than the intra-assay variation35.  
The sensitivity of a two-fold rise in titer has been reported to be 90-92% when 
compared to culture91, 92. However, since there is no highly sensitive gold standard diagnostic 
method, it is difficult to calculate robust specificities. Mertsola et al.91 reported the specificity 
to be 72% when compared to culture. This is probably an underestimation as a substantial 
proportion of serology positive/culture negative samples were likely true positives not 
detected by culture as there are no competing hypotheses to explain a rise in titer other than 
infection in the absence of recent vaccination81.  
2. Single serology 
 
Due to the limitations regarding the correct use of paired sera, methods to define a 
single antibody titer suggestive of recent pertussis infection have been developed. Diagnosis 
based on a single serum titer is believed possible because both IgG and IgA antibody titers 
typically drop to low levels within one to two years post exposure97, 100-102. Therefore, a high 
titer more than two years post vaccination is likely evidence of recent infection. 
A single serum method popular in the 1980s and 1990s used the criterion that  any 
person with an antibody titer greater than 3 standard deviations above the mean value of the 
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 titer in the negative control population was considered infected with B. pertussis7, 8, 90, 92, 96, 
103, 104. Similarly, titers greater than the 99.9th percentile105, 106 and 98th percentile point63 of 
the negative controls have also been used as the diagnostic threshold. In addition, a single 
titer using an absolute titer cut-off has been used to diagnose pertussis in Massachusetts64, 107 
since 1994, with reported 63% sensitivity.  
A landmark study conducted in the Netherlands by de Melker et al.94 in 2000 made 
substantial progress in establishing a single cut-off value indicative of pertussis infection. 
The study analyzed 7,756 sera for anti-PT IgG. Of these, 3,491 samples were drawn from 
patients with at least a four-fold increase in anti-PT IgG, 89 samples were from patients with 
laboratory (culture or PCR) confirmed pertussis, and 57 were from individuals with a clinical 
diagnosis of pertussis. Follow-up was conducted for a mean duration of 1.4 years. A titer of 
100 Dutch ELISA Units was shown to be 76.4% sensitive and 99.2% specific for recent 
pertussis infection. While an international standard has not yet been developed, criteria 
established by the European Sero-Epidemiology Network (ESEN) has allowed for 
comparison between Dutch, French, British, German, Swedish, and Italian units108. Since this 
publication, at least four studies have used this single serum method for pertussis diagnosis70, 
109-111. A comparable cut-off value of 94 EU/mL that is 80% sensitive and 93% specific has 
been recently published in the U.S.112  
In conclusion, major advances in the serological diagnosis of pertussis have been 
made since its introduction almost a century ago but disadvantages remain important. The 
main advantage of serologic methods over PCR and culture is that antibiotic therapy does not 
affect the interpretation of results113 and the sensitivity of the single titer method does not 
decrease but increases with time since infection. A major disadvantage is recent vaccination 
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 obfuscates the interpretation of the results and caution should be used when interpreting 
serological results in persons previously vaccinated. While traditionally this has only 
impacted vaccinated children age less than two years and four to six years, the recent 
licensure of the acellular boosters for adolescents and adults78 will affect persons from all age 
ranges, greatly limiting the usefulness of serology as a diagnostic tool. Second, while paired 
serum samples using a four-fold increase in anti-PT antibody titer may be a useful in research 
studies, the requirement for two blood samples collected at specific time points and the 
consequent waiting time to make a diagnosis (4 to 6 weeks after presentation) renders this 
method essentially useless in the clinical setting. The single serum method is promising, but 
there is no standardized method to conduct serology114 as the variability between commercial 
ELISA kits has not been resolved115. Thus, more work is needed to standardize the cut-off 
levels between laboratories and between countries with different levels of pertussis 
endemicity.  
H. Conclusion 
 
While culture is still considered the gold standard for the diagnosis of pertussis, vast 
progress has been made in the development of alternative diagnostic methods. PCR has been 
shown to be a highly specific method with greater sensitivity than culture. While PCR is 
commonly used for pertussis research, recent efforts to develop an internationally accepted 
standard will likely result in its increased use in clinical and outbreak settings. The recent 
development of a reliable diagnostic method using a single serum sample presents a new and 
simplified approach to pertussis diagnosis, but its use may become limited if high coverage 
rates of the recently recommended adolescent and adult pertussis vaccination are achieved.  
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 Selection of the optimal test will depend on several factors.  The time interval 
between presentation and availability of results is of major importance in clinical settings. 
Randomized clinical trials, outbreak investigations and pertussis surveillance may all require 
different levels of sensitivity and specificity depending on the research hypothesis. A 
summary of the methods reviewed, their sensitivities, specificities, and principle limitations 
are presented in Table 7.1. 
In order to get a more accurate understanding of the trade-off between specificity and 
sensitivity of the different diagnostic methods, further research should be performed to assess 
the sensitivity and specificity of the various standardized diagnostic methods across 
populations.  In addition, changes in sensitivity and specificity when two or more diagnostic 
criteria are used in combination should be evaluated to determine the gain in diagnostic 
performance when using multiple diagnostic methods.   
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 Table 7.1. Diagnostic test, reported sensitivities and specificities, and principle limitations. 
Diagnostic method Sensitivity Specificity Limitations 
Culture 12%-60%30, 
35-39 
100%34 Low sensitivity, 5-day delay between 
sample collection  and results 
 
PCR 70%-99%30, 
36, 37, 39, 62, 63, 
70 
86%-100% 
30, 38, 39, 56, 57, 
74, 75 
Current lack of internationally 
standardized method, occurrence of 
laboratory contamination with 
consequent false positive results 
 
Paired Sera 90%-92%92, 
93 
72%-
100%91, 94 
4 to 6 week delay between sample 
collection  and results , difficulty in 
correct timing collection of samples 
 
Single Sera 63%-76%94, 
107 
99%94 Lack of interlaboratory validation of 
antibody titer cut-off 
 
Clinical diagnosis 
(Symptoms & Signs) 
67%-89%* 
22, 23 
52%-94%* 
22, 23 
Low sensitivity in the vaccine era due to 
high proportion of atypical and mild 
pertussis cases 
*Sensitivity and specificities for clinical diagnosis based on presence of cough for 2 or more 
weeks calculated during outbreak settings. 
 100 
 I. References 
 
1. Mortimer Jr EA. Pertussis (Whooping Cough). In: Krugman S, Katz SL, Gershon 
AA, Wilfert CM, eds. Infectious Diseases of Chidren. 9th ed. St. Louis: Mosby Year 
Book; 1992:299-313. 
 
2. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in 
pertussis among infants in the United States, 1980-1999. Jama. Dec 10 
2003;290(22):2968-2975. 
 
3. Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general 
practice population study. Bmj. Feb 4 1995;310(6975):299-302. 
 
4. Gordon J, Hood R. Whooping Cough and its Epidemiological Anomalies. Preventive 
Medicine and Epidemiology. 1951;222:333-361. 
 
5. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. Vol 
1. 5th ed. Philadelphia: Churchill Livingstone; 2000. 
 
6. Dodhia H, Crowcroft NS, Bramley JC, Miller E. UK guidelines for use of 
erythromycin chemoprophylaxis in persons exposed to pertussis. J Public Health 
Med. Sep 2002;24(3):200-206. 
 
7. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in 
families: antibody correlates of infection and symptomatology. J Infect Dis. Mar 
1990;161(3):480-486. 
 
8. Long SS, Lischner HW, Deforest A, Clark JL. Serologic evidence of subclinical 
pertussis in immunized children. Pediatr Infect Dis J. Oct 1990;9(10):700-705. 
 
9. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? 
Pediatr Infect Dis J. Nov 2004;23(11):985-989. 
 
10. Deeks S, De Serres G, Boulianne N, et al. Failure of physicians to consider the 
diagnosis of pertussis in children. Clin Infect Dis. Apr 1999;28(4):840-846. 
 
11. Groseclose SL, Brathwaite WS, Hall PA, et al. Summary of notifiable diseases--
United States, 2002. MMWR Morb Mortal Wkly Rep. Apr 30 2004;51(53):1-84. 
 
12. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the 
United States: increasing reported incidence among adolescents and adults, 1990-
1996. Clin Infect Dis. Jun 1999;28(6):1230-1237. 
 
 101 
 13. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis 
among young infants in the United States in the 1990s. Pediatr Infect Dis J. Jul 
2003;22(7):628-634. 
 
14. Ranganathan S, Tasker R, Booy R, Habibi P, Nadel S, Britto J. Pertussis is increasing 
in unimmunized infants: is a change in policy needed? Arch Dis Child. Mar 
1999;80(3):297-299. 
 
15. Heininger U, Stehr K, Cherry JD. Serious pertussis overlooked in infants. Eur J 
Pediatr. May 1992;151(5):342-343. 
 
16. Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. Clinical manifestations of Bordetella 
pertussis infection in immunized children and young adults. Chest. May 
1999;115(5):1254-1258. 
 
17. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and 
adults. J Infect Dis. Jul 2000;182(1):174-179. 
 
18. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with 
persistent cough. Jama. Apr 5 1995;273(13):1044-1046. 
 
19. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and 
laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in 
Germany. Pediatr Infect Dis J. Jun 1993;12(6):504-509. 
 
20. Program NI. Pertussis. In: http://www.cdc.gov/nip/publications/pink/pert.pdf, ed: 
Centers for Disease Control and Prevention; 2004. 
 
21. Team DoVaBVAaM. Pertussis.  http://www.who.int/vaccines-
surveillance/deseasedesc/RSS_pertus.htm. The World Health Organization. Available 
at: http://www.who.int/vaccines-surveillance/deseasedesc/RSS_pertus.htm. Accessed 
September 27, 2004, 2004. 
 
22. Steketee RW, Burstyn DG, Wassilak SG, et al. A comparison of laboratory and 
clinical methods for diagnosing pertussis in an outbreak in a facility for the 
developmentally disabled. J Infect Dis. Mar 1988;157(3):441-449. 
 
23. Patriarca PA, Biellik RJ, Sanden G, et al. Sensitivity and specificity of clinical case 
definitions for pertussis. Am J Public Health. Jul 1988;78(7):833-836. 
 
24. Wirsing von Konig CH, Campins-Marti M, Finn A, Guiso N, Mertsola J, Liese J. 
Pertussis immunization in the global pertussis initiative European region: 
recommended strategies and implementation considerations. Pediatr Infect Dis J. 
May 2005;24(5 Suppl):S87-92. 
 
 102 
 25. Versteegh FG, Schellekens J, Fleer A, Roord JJ. Pertussis: a concise historical review 
including diagnosis, incience, clinical manifestations and the role of treatment and 
vaccination in management. Reviews in Medical Microbiology. 2005;16(3):79-89. 
 
26. Friedman RL. Pertussis: the disease and new diagnostic methods. Clin Microbiol Rev. 
Oct 1988;1(4):365-376. 
 
27. Granstrom G, Wretlind B, Granstrom M. Diagnostic value of clinical and 
bacteriological findings in pertussis. J Infect. Jan 1991;22(1):17-26. 
 
28. Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin 
Microbiol. Sep 1977;6(3):303-309. 
 
29. Aoyama T, Goto A, Iwai H, et al. Simple and efficient method for clinical isolation of 
Bordetella pertussis. Dev Biol Stand. 1991;73:185-192. 
 
30. Dragsted DM, Dohn B, Madsen J, Jensen JS. Comparison of culture and PCR for 
detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory 
conditions. J Med Microbiol. Aug 2004;53(Pt 8):749-754. 
 
31. Hewlett E, ed. Bordetella Species. 5th ed. Philadelphia: Churchill Livingstone; 2000. 
Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases; 
No. 1. 
 
32. Katzko G, Hofmeister M, Church D. Extended incubation of culture plates improves 
recovery of Bordetella spp. J Clin Microbiol. Jun 1996;34(6):1563-1564. 
 
33. Hallander HO, Reizenstein E, Renemar B, Rasmuson G, Mardin L, Olin P. 
Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella 
pertussis. J Clin Microbiol. Jan 1993;31(1):50-52. 
 
34. Onorato IM, Wassilak SG. Laboratory diagnosis of pertussis: the state of the art. 
Pediatr Infect Dis J. Feb 1987;6(2):145-151. 
 
35. Lind-Brandberg L, Welinder-Olsson C, Lagergard T, Taranger J, Trollfors B, 
Zackrisson G. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella 
parapertussis infections. J Clin Microbiol. Mar 1998;36(3):679-683. 
 
36. He Q, Mertsola J, Soini H, Viljanen MK. Sensitive and specific polymerase chain 
reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens. J 
Pediatr. Mar 1994;124(3):421-426. 
 
37. Schlapfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification 
of Bordetella pertussis infections in vaccinees and family members in a pertussis 
vaccine efficacy trial in Germany. Pediatr Infect Dis J. Mar 1995;14(3):209-214. 
 
 103 
 38. Templeton KE, Scheltinga SA, Van Der Zee A, et al. Evaluation of real-time PCR for 
detection of and discrimination between Bordetella pertussis, Bordetella 
parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol. Sep 
2003;41(9):4121-4126. 
 
39. Chan EL, Antonishyn N, McDonald R, et al. The use of TaqMan PCR assay for 
detection of Bordetella pertussis infection from clinical specimens. Arch Pathol Lab 
Med. Mar 2002;126(2):173-176. 
 
40. Grimprel E, Begue P, Anjak I, Betsou F, Guiso N. Comparison of polymerase chain 
reaction, culture, and western immunoblot serology for diagnosis of Bordetella 
pertussis infection. J Clin Microbiol. Oct 1993;31(10):2745-2750. 
 
41. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. 
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and 
pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven 
evolution. Infect Immun. Feb 1998;66(2):670-675. 
 
42. Arico B, Rappuoli R. Bordetella parapertussis and Bordetella bronchiseptica contain 
transcriptionally silent pertussis toxin genes. J Bacteriol. Jul 1987;169(6):2847-2853. 
 
43. Heininger U, Stehr K, Schmitt-Grohe S, et al. Clinical characteristics of illness caused 
by Bordetella parapertussis compared with illness caused by Bordetella pertussis. 
Pediatr Infect Dis J. May 1994;13(4):306-309. 
 
44. Liese JG, Renner C, Stojanov S, Belohradsky BH. Clinical and epidemiological 
picture of B pertussis and B parapertussis infections after introduction of acellular 
pertussis vaccines. Arch Dis Child. Aug 2003;88(8):684-687. 
 
45. Letowska I, Hryniewicz W. Epidemiology and characterization of Bordetella 
parapertussis strains isolated between 1995 and 2002 in and around Warsaw, Poland. 
Eur J Clin Microbiol Infect Dis. Jul 2004;23(6):499-501. 
 
46. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused 
by Bordetella pertussis and Bordetella parapertussis in an immunized population. 
Jama. Sep 19 1998;280(7):635-637. 
 
47. Linnemann CC, Jr., Bass JW, Smith MH. The carrier state in pertussis. Am J 
Epidemiol. Nov 1968;88(3):422-427. 
 
48. Tilley PA, Kanchana MV, Knight I, Blondeau J, Antonishyn N, Deneer H. Detection 
of Bordetella pertussis in a clinical laboratory by culture, polymerase chain reaction, 
and direct fluorescent antibody staining; accuracy, and cost. Diagn Microbiol Infect 
Dis. May 2000;37(1):17-23. 
 
 104 
 49. Halperin SA, Bortolussi R, Wort AJ. Evaluation of culture, immunofluorescence, and 
serology for the diagnosis of pertussis. J Clin Microbiol. Apr 1989;27(4):752-757. 
 
50. Hallander HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis. 
Jun 1999;28 Suppl 2:S99-106. 
 
51. Ewanowich CA, Chui LW, Paranchych MG, Peppler MS, Marusyk RG, Albritton 
WL. Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant 
direct fluorescent-antibody and culture results by using polymerase chain reaction 
methodology. J Clin Microbiol. Jul 1993;31(7):1715-1725. 
 
52. McNicol P, Giercke SM, Gray M, et al. Evaluation and validation of a monoclonal 
immunofluorescent reagent for direct detection of Bordetella pertussis. J Clin 
Microbiol. Nov 1995;33(11):2868-2871. 
 
53. Gilligan PH, Fisher MC. Importance of culture in laboratory diagnosis of Bordetella 
pertussis infections. J Clin Microbiol. Nov 1984;20(5):891-893. 
 
54. Houard S, Hackel C, Herzog A, Bollen A. Specific identification of Bordetella 
pertussis by the polymerase chain reaction. Res Microbiol. Sep 1989;140(7):477-487. 
 
55. Farrell DJ, McKeon M, Daggard G, Loeffelholz MJ, Thompson CJ, Mukkur TK. 
Rapid-cycle PCR method to detect Bordetella pertussis that fulfills all consensus 
recommendations for use of PCR in diagnosis of pertussis. J Clin Microbiol. Dec 
2000;38(12):4499-4502. 
 
56. Kosters K, Reischl U, Schmetz J, Riffelmann M, Wirsing von Konig CH. Real-time 
LightCycler PCR for detection and discrimination of Bordetella pertussis and 
Bordetella parapertussis. J Clin Microbiol. Jun 2002;40(5):1719-1722. 
 
57. Cloud JL, Hymas WC, Turlak A, et al. Description of a multiplex Bordetella pertussis 
and Bordetella parapertussis LightCycler PCR assay with inhibition control. Diagn 
Microbiol Infect Dis. Aug 2003;46(3):189-195. 
 
58. Olcen P, Backman A, Johansson B, et al. Amplification of DNA by the polymerase 
chain reaction for the efficient diagnosis of pertussis. Scand J Infect Dis. 
1992;24(3):339-345. 
 
59. van der Zee A, Agterberg C, Peeters M, Schellekens J, Mooi FR. Polymerase chain 
reaction assay for pertussis: simultaneous detection and discrimination of Bordetella 
pertussis and Bordetella parapertussis. J Clin Microbiol. Aug 1993;31(8):2134-2140. 
 
60. Meade BD, Bollen A. Recommendations for use of the polymerase chain reaction in 
the diagnosis of Bordetella pertussis infections. J Med Microbiol. Jul 1994;41(1):51-
55. 
 
 105 
 61. Riffelmann M, Wirsing von Konig CH, Caro V, Guiso N. Nucleic Acid amplification 
tests for diagnosis of Bordetella infections. J Clin Microbiol. Oct 2005;43(10):4925-
4929. 
 
62. Glare EM, Paton JC, Premier RR, Lawrence AJ, Nisbet IT. Analysis of a repetitive 
DNA sequence from Bordetella pertussis and its application to the diagnosis of 
pertussis using the polymerase chain reaction. J Clin Microbiol. Sep 
1990;28(9):1982-1987. 
 
63. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation 
of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: 
comparison with culture and serology using samples from patients with suspected 
whooping cough from a highly immunized population. J Infect Dis. Jul 
1996;174(1):89-96. 
 
64. Yih WK, Silva EA, Ida J, Harrington N, Lett SM, George H. Bordetella holmesii-like 
organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg 
Infect Dis. May-Jun 1999;5(3):441-443. 
 
65. van der Zee A, Agterberg C, van Agterveld M, Peeters M, Mooi FR. Characterization 
of IS1001, an insertion sequence element of Bordetella parapertussis. J Bacteriol. Jan 
1993;175(1):141-147. 
 
66. Sloan LM, Hopkins MK, Mitchell PS, et al. Multiplex LightCycler PCR assay for 
detection and differentiation of Bordetella pertussis and Bordetella parapertussis in 
nasopharyngeal specimens. J Clin Microbiol. Jan 2002;40(1):96-100. 
 
67. Grimprel E, Njamkepo E, Begue P, Guiso N. Rapid diagnosis of pertussis in young 
infants: comparison of culture, PCR, and infant's and mother's serology. Clin Diagn 
Lab Immunol. Nov 1997;4(6):723-726. 
 
68. Douglas E, Coote JG, Parton R, McPheat W. Identification of Bordetella pertussis in 
nasopharyngeal swabs by PCR amplification of a region of the adenylate cyclase 
gene. J Med Microbiol. Feb 1993;38(2):140-144. 
 
69. Li Z, Jansen DL, Finn TM, et al. Identification of Bordetella pertussis infection by 
shared-primer PCR. J Clin Microbiol. Mar 1994;32(3):783-789. 
 
70. Fry NK, Tzivra O, Li YT, et al. Laboratory diagnosis of pertussis infections: the role 
of PCR and serology. J Med Microbiol. Jun 2004;53(Pt 6):519-525. 
 
71. Chia JH, Su LH, Lin PY, et al. Comparison of multiplex polymerase chain reaction, 
culture, and serology for the diagnosis of Bordetella pertussis infection. Chang Gung 
Med J. Jul 2004;27(6):408-415. 
 
 106 
 72. Heininger U, Schmidt-Schlapfer G, Cherry JD, Stehr K. Clinical validation of a 
polymerase chain reaction assay for the diagnosis of pertussis by comparison with 
serology, culture, and symptoms during a large pertussis vaccine efficacy trial. 
Pediatrics. Mar 2000;105(3):E31. 
 
73. He Q, Schmidt-Schlapfer G, Just M, et al. Impact of polymerase chain reaction on 
clinical pertussis research: Finnish and Swiss experiences. J Infect Dis. Dec 
1996;174(6):1288-1295. 
 
74. Qin X, Turgeon DK, Ingersoll BP, et al. Bordetella pertussis PCR: simultaneous 
targeting of signature sequences. Diagn Microbiol Infect Dis. Sep 2002;43(4):269-
275. 
 
75. Kosters K, Riffelmann M, Wirsing von Konig CH. Evaluation of a real-time PCR 
assay for detection of Bordetella pertussis and B. parapertussis in clinical samples. J 
Med Microbiol. Jun 2001;50(5):436-440. 
 
76. Taranger J, Trollfors B, Lind L, Zackrisson G, Beling-Holmquist K. Environmental 
contamination leading to false-positive polymerase chain reaction for pertussis. 
Pediatr Infect Dis J. Oct 1994;13(10):936-937. 
 
77. Erlandsson A, Backman A, Tornqvist E, Olcen P. PCR assay or culture for diagnosis 
of Bordetella pertussis in the routine diagnostic laboratory? J Infect. Nov 
1997;35(3):221-224. 
 
78. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and 
pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and 
acellular pertussis vaccines: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). Early Release. MMWR Morb Mortal Wkly Rep. 
February 23, 2006 2006;55:1-43. 
 
79. Trollfors B, Taranger J, Lagergard T, et al. Efficacy of a monocomponent pertussis 
toxoid vaccine after household exposure to pertussis. J Pediatr. Apr 1997;130(4):532-
536. 
 
80. Biellik RJ, Patriarca PA, Mullen JR, et al. Risk factors for community- and 
household-acquired pertussis during a large-scale outbreak in central Wisconsin. J 
Infect Dis. Jun 1988;157(6):1134-1141. 
 
81. Muller FM, Hoppe JE, Wirsing von Konig CH. Laboratory diagnosis of pertussis: 
state of the art in 1997. J Clin Microbiol. Oct 1997;35(10):2435-2443. 
 
82. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson 
EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. 
Pediatrics. Jan 1994;93(1):37-43. 
 
 107 
 83. Vincent JM, Cherry JD, Nauschuetz WF, et al. Prolonged afebrile nonproductive 
cough illnesses in American soldiers in Korea: a serological search for causation. Clin 
Infect Dis. Mar 2000;30(3):534-539. 
 
84. Trollfors B, Lagergard T, Gunnarsson E, Taranger J. Determination of pertactin IgG 
antibodies for the diagnosis of pertussis. Clin Microbiol Infect. Aug 2003;9(7):585-
589. 
 
85. Nagel J, Poot-Scholtens EJ. Serum IgA antibody to Bordetella pertussis as an 
indicator of infection. J Med Microbiol. Nov 1983;16(4):417-426. 
 
86. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical 
manifestations of respiratory infections due to Bordetella pertussis and other 
Bordetella subspecies. Clin Microbiol Rev. Apr 2005;18(2):326-382. 
 
87. Heininger U, Cherry JD, Christenson PD, et al. Comparative study of Lederle/Takeda 
acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis 
vaccines in infants in Germany. Vaccine. Jan 1994;12(1):81-86. 
 
88. Cherry JD, Beer T, Chartrand SA, et al. Comparison of values of antibody to 
Bordetella pertussis antigens in young German and American men. Clin Infect Dis. 
May 1995;20(5):1271-1274. 
 
89. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after 
immunization of adolescents and adults with an acellular pertussis vaccine: the 
APERT Study. J Infect Dis. Aug 1 2004;190(3):535-544. 
 
90. Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection 
in university students. Clin Infect Dis. Feb 1992;14(2):464-471. 
 
91. Mertsola J, Ruuskanen O, Kuronen T, Meurman O, Viljanen MK. Serologic diagnosis 
of pertussis: evaluation of pertussis toxin and other antigens in enzyme-linked 
immunosorbent assay. J Infect Dis. May 1990;161(5):966-971. 
 
92. Granstrom M, Granstrom G, Lindfors A, Askelof P. Serologic diagnosis of whooping 
cough by an enzyme-linked immunosorbent assay using fimbrial hemagglutinin as 
antigen. J Infect Dis. Dec 1982;146(6):741-745. 
 
93. Mertsola J, Ruuskanen O, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. J 
Pediatr. Sep 1983;103(3):359-363. 
94. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and 
sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a 
single serum sample for diagnosis of infection with Bordetella pertussis. J Clin 
Microbiol. Feb 2000;38(2):800-806. 
 
 108 
 95. Conway SP, Balfour AH, Ross H. Serologic diagnosis of whooping cough by 
enzyme-linked immunosorbent assay. Pediatr Infect Dis J. Aug 1988;7(8):570-574. 
 
96. Wirsing von Konig CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: 
frequency of transmission after household exposure. Lancet. Nov 18 
1995;346(8986):1326-1329. 
 
97. Hodder SL, Cherry JD, Mortimer Jr EA, Ford AB, Gornbein J, Papp K. Antibody 
responses to Bordetella pertussis antigens and clinical correlations in elderly 
community residents. Clin Infect Dis. Jul 2000;31(1):7-14. 
 
98. Jackson LA, Cherry JD, Wang SP, Grayston JT. Frequency of serological evidence of 
Bordetella infections and mixed infections with other respiratory pathogens in 
university students with cough illnesses. Clin Infect Dis. Jul 2000;31(1):3-6. 
 
99. Langley JM, Halperin SA, Boucher FD, Smith B. Azithromycin is as effective as and 
better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics. 
Jul 2004;114(1):e96-101. 
 
100. Teunis PF, van der Heijden OG, de Melker HE, Schellekens JF, Versteegh FG, 
Kretzschmar ME. Kinetics of the IgG antibody response to pertussis toxin after 
infection with B. pertussis. Epidemiol Infect. Dec 2002;129(3):479-489. 
 
101. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van 
Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the 
Netherlands: observations on surveillance data. Emerg Infect Dis. Jul-Aug 
2000;6(4):348-357. 
 
102. Pebody RG, Gay NJ, Giammanco A, et al. The seroepidemiology of Bordetella 
pertussis infection in Western Europe. Epidemiol Infect. Feb 2005;133(1):159-171. 
 
103. Robertson PW, Goldberg H, Jarvie BH, Smith DD, Whybin LR. Bordetella pertussis 
infection: a cause of persistent cough in adults. Med J Aust. May 18 
1987;146(10):522-525. 
 
104. Zackrisson G, Krantz I, Lagergard T, et al. Antibody response to pertussis toxin in 
patients with clinical pertussis measured by enzyme-linked immunosorbent assay. 
Eur J Clin Microbiol Infect Dis. Apr 1988;7(2):149-154. 
105. Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella 
pertussis infections in adults. Clin Infect Dis. Sep 1995;21(3):639-642. 
 
106. Schmitt-Grohe S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr K. Pertussis 
in German adults. Clin Infect Dis. Oct 1995;21(4):860-866. 
 
 109 
 107. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: 
incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis. Jun 
1994;169(6):1297-1305. 
 
108. Giammanco A, Chiarini A, Maple PA, et al. European Sero-Epidemiology Network: 
standardisation of the assay results for pertussis. Vaccine. Dec 8 2003;22(1):112-120. 
 
109. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK 
infants. Arch Dis Child. Sep 2003;88(9):802-806. 
 
110. Nardone A, Pebody RG, Maple PA, Andrews N, Gay NJ, Miller E. Sero-
epidemiology of Bordetella pertussis in England and Wales. Vaccine. Mar 12 
2004;22(9-10):1314-1319. 
 
111. Horby P, Macintyre CR, McIntyre PB, et al. A boarding school outbreak of pertussis 
in adolescents: value of laboratory diagnostic methods. Epidemiol Infect. Apr 
2005;133(2):229-236. 
 
112. Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff 
points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, 
and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol. 
Nov 2004;11(6):1045-1053. 
 
113. Granstrom G, Granstrom M. Effect of erythromycin treatment on antibody responses 
in pertussis. Scand J Infect Dis. 1994;26(4):453-457. 
 
114. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and 
infants. Lancet Infect Dis. Dec 2002;2(12):744-750. 
 
115. Kosters K, Riffelmann M, Dohrn B, von Konig CH. Comparison of five commercial 
enzyme-linked immunosorbent assays for detection of antibodies to Bordetella 
pertussis. Clin Diagn Lab Immunol. May 2000;7(3):422-426. 
 
 110 
  
VIII. THE PROTECTIVE INHIBITORY ROLE OF MATERNAL PERTUSSIS 
ANTIBIODIES 
 
Annelies Van Rie, MD PhD*; Aaron Wendelboe, MSPH*; Janet Englund, MD†
 
From the *Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel 
Hill, NC; and the †Department of Pediatrics, Children's Hospital and Regional Medical 
Center, University of Washington, Seattle, WA 
 
 
 
(Published in the Pediatric Infectious Disease Journal. 2005; 24(5suppl):S62-5) 
 
 A. Abstract 
Pertussis remains a serious infection in young infants. Most deaths occur in the first 3 
months of life, before administration of the first dose of pertussis vaccine. Pertussis 
antibodies are transferred from mother to infant; but because of the lack of serologic 
correlates of protection, it is difficult to determine the proportion of infants born with a 
protective concentration of maternal antibodies. Indirect evidence suggests that maternal 
antibodies provide short lived protection against fatal pertussis. It is hoped that the protection 
of young infants could be enhanced by maternal or neonatal vaccination. The possibility of 
protecting young infants against pertussis by immunizing their mothers during pregnancy 
was investigated in the 1930s and 1940s; no further studies have been published since. 
Recent animal and human studies have provided evidence that neonatal immunization with 
acellular pertussis vaccine can efficiently prime T and B cells and act as a basis for future 
immune response. The limited data on neonatal and maternal pertussis immunization are 
promising and call for further research to reduce the vulnerability of young infants to 
pertussis disease. 
B. Introduction 
 
In the early to mid 1900’s, whooping cough caused more deaths during the first year 
of life than measles, diphtheria or scarlet fever1. Since the introduction of diphtheria-tetanus-
pertussis whole cell (DTPw) immunization in the late 1940’s, the incidence of pertussis 
dropped dramatically. Pertussis however has remained a serious infection in young infants 
and the reported incidence in infants has always been high compared to other age groups2. In 
the 1990s pertussis in young infants was responsible for more than 60% of pertussis related 
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 complications, 86% of hospitalizations and 92% of pertussis deaths in the US.2 Pertussis 
deaths occur most often in the first 3 months of life, before administration of the first dose of 
pertussis vaccine3.  
In this paper, the role of maternal antibodies in protection against pertussis and the 
potential interference of maternal antibodies with active immunization (DTPw and DTPa) in 
the first months of life are reviewed.  
C. Placental transport of maternal antibodies 
 
Immunoglobulin G (IgG) is transported from mother to infant across the placenta, 
predominantly during the third trimester. IgG1 is the most efficiently transferred 
immunoglobulin subclass4, 5. Placental transfer of IgG is initiated by the binding of maternal 
IgG to Fc receptors in the placenta. The exact mechanism of IgG transport across the 
endothelium of fetal capillaries is not yet well understood4. The active placental transfer of 
IgG is specific and has variable efficacy, resulting in cord blood levels that are as low as 20% 
of maternal levels or exceed maternal levels by 200%6. Most data on placental transfer of 
anti-pertussis IgG date from the 1940’s. As measured by the opsonophagocytic index, 
agglutination, or complement fixation, these data demonstrated transplacental transfer of 
pertussis IgG at a relatively low efficiency1, 7-12. In only 2 to 12% of mother-infant pairs did 
the infants’ titers exceed maternal levels. These historic data also showed a direct correlation 
between antibody concentrations in mother-infant pairs, with the highest titers found in 
infants born to mothers with a history of pertussis or maternal pertussis immunization1, 9, 13, 
14. More recent studies have shown conflicting results on the relative efficiency of the 
transplacental transfer of specific maternal pertussis IgG.  While one study demonstrated that 
pertussis toxin (PT) IgG might be more efficiently transferred than IgG against other 
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 pertussis antigens15, other studies found no difference among the different pertussis 
antigens16, 17. 
D. Protection of infants by maternal antibodies 
 
It was observed as early as the1930s that mothers transfer antibodies to their infants, 
thus providing infants with some degree of protection against diseases such as measles, 
diphtheria and poliomyelitis1, 9, 18. Maternal antibodies can protect infants from infections and 
modify the severity of infectious diseases in infants for a varying period of time, depending 
on the level of placental transmission and the rate of decay of passive acquired antibodies. 
While there is a highly significant correlation between the level of vaccine-induced serum PT 
IgG and protection against pertussisis19, no serological correlates of protection exist for 
pertussis. Therefore, it is difficult to determine the proportion of infants born with a 
protective level of maternal antibodies. Pertussis notification data from the pre-vaccine era 
provide indirect evidence that maternal antibodies provide short-lived protection against fatal 
pertussis by demonstrating that the rate of pertussis deaths in the first month of life was 
approximately one third of that in the second and third months of life20, 21. Pertussis 
surveillance data in the vaccine era do not indicate a difference in the notification rate during 
the first month of life and the subsequent 5 months of life. This might be explained by a 
reduced level of circulation of Bordetella pertussis following the introduction of mass 
immunization, which would lead to a reduced rate of (a)symptomatic boosting of the immune 
system from natural infection. This would then result in reduced levels of circulating 
pertussis IgG in young adults and thus reduced efficiency of transfer of maternal antibodies. 
This hypothesis is supported by serological data demonstrating that 30 to 50% of pregnant 
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 women in the pre-vaccine era had circulating antibodies against pertussis8, 11 while recent 
studies found low PT-IgG levels (GMT < 10 EU/ml) in the majority of women17, 22.
There is scanty evidence from animal experiment studies that maternal PT IgA and 
IgG transferred via colostrum or breastmilk could be protective9, 23.  
E. Possibility of enhanced passive protection through maternal immunization 
 
As early as the 1930s, researchers have tried to protect young infants against pertussis 
by immunizing pregnant women during the third trimester13. Following maternal 
immunization, infant titers of pertussis antibodies ranged from 50% of maternal titers to 
approximately equal titers in mother-infant pairs1, 9, 13, 14. Babies of immunized mothers had 
approximately 2.9 times greater levels of antibodies to pertussis than control babies14. 
Unfortunately, it has been impossible to assess if infant titers resulting from maternal 
immunization were protective as no clear serological correlates of protection exists.  Animal 
studies were able to demonstrate protection in mice that received serum from infants born to 
mothers immunized during pregnancy and were challenged with virulent B. pertussis1.  
Maternal PT and FHA IgG have a half-life of approximately 5 weeks (36.3 days and 
40.3 days, respectively) and drop to undetectable levels by 4 months of life in infants whose 
mothers were not immunized or by 6 months of life in infants whose mothers were 
immunized9, 15, 24.  
F. Interference of maternal antibodies with active infant immunization and the 
potential of neonatal vaccination 
 
Humoral Immunity  
 In the 1930s, it was recommended that infant immunization be carried out during the 
second half-year of life because young infants did not appear to respond as well as older 
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 infants to the pertussis vaccine13. Studies in the 1940s demonstrated that adequate immunity 
against pertussis could be achieved by 6 months of age if the first dose was given at 2 months 
of age7, 9. Immunizations given within 24 hours of birth resulted in a decreased humoral 
immune response or “temporary immune paralysis”21, 24, 25. Observations in a recent murine 
model confirm the findings of transient unresponsiveness following neonatal vaccination 
with whole cell pertussis vaccine, and further indicate that this phenomenon is antigen 
specific and does not imply the induction of long-lasting immune tolerance or the absence of 
protective efficacy26.  
The reason for the poor immune response in infants vaccinated at birth (or shortly 
thereafter) is believed to be due to the immaturity of the neonatal immune response and 
competing maternal antibodies. Historic studies demonstrated that the immune response to 
immunization with whole cell pertussis vaccine was lower in infants with high cord blood PT 
IgG levels compared to infants with a low level of circulating maternal antibodies7, 11, 14, 24, 25, 
27, 28. In contrast to maternal antibodies inhibiting the infants’ immune response to whole cell 
pertussis vaccine, immunization with acellular pertussis vaccine is not inhibited by 
circulating maternal antibodies15, 22, 26. Both animal and human studies have recently 
provided further evidence of the potential of neonatal immunization with acellular pertussis 
vaccine. Immunization with acellular pertussis vaccine in neonatal (1-week-old) mice 
mounted as strong a response as in infant (3-week-old) mice26. A human study suggests that 
it might currently be possible to induce early protection against pertusis as 10% of infants 
vaccinated at birth reached a 4-fold increase in PT IgG levels, and a rapid induction of 
antibodies after the second dose was observed in those infants vaccinated at birth17.  
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 G. T-cell Mediated Immunity 
 
The inhibititory influence of maternal antibodies on infant immune responses is B-cell 
determinant specific and leaves the infant T-cell responses largely unaffected29. The weak 
neonatal T-cell mediated cytotoxicity and T-cell help for B-cell differentiation results in an 
immature immune response. Even though neonatal immunization does not generally lead to 
rapid antibody responses, strong induction of pertussis-specific antibody secreting cells and 
memory cells can be achieved and subsequent vaccine doses will induce infant antibody 
responses as soon as circulating maternal antibody titers decline below the infant response 
threshold, as demonstrated by experiments in which neonatal mice were vaccinated with 
acellular pertussis vaccine. Neonatal immunization may thus efficiently prime B and T cells 
and act as a basis for future immune response26. 
H.  Conclusion 
 
Despite immense progress in reducing the morbidity and mortality of pertussis through 
universal immunization, pertussis in infants too young to be fully vaccinated remains a public 
health problem worldwide.   New vaccination strategies are being considered to improve 
pertussis control during the first months of life. Routine vaccination of adolescents and 
adults, and selective vaccination of adult contacts of newborns aims at reducing transmission 
of B. pertussis from adults to infants. Considerable logistic issues, high cost and unknown 
impact challenge these vaccination strategies.  Alternative options are maternal and neonatal 
immunization. Questions of vaccine liability and potential impact on infant immune 
responses remain the greatest barriers to development and implementation of maternal 
pertussis vaccination.  Data on neonatal immunization with acellular pertussis is limited but 
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 promising. Research efforts should increasingly focus on maternal or neonatal vaccination to 
reduce the vulnerability of young infants to pertussis.   
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 A. Abstract 
 
Despite decades of high vaccination coverage, pertussis has remained endemic and 
re-emerged as a public health problem in many countries in the past two decades. Waning of 
vaccine-induced immunity has been cited as one of the reasons for the observed 
epidemiological trend. A review of the published data on duration of immunity reveals 
estimates that infection-acquired immunity against pertussis disease wanes after 4 to 20 years 
and protective immunity following vaccination wanes after 4 to 12 years. Further research 
into the rate of waning of vaccine-acquired immunity will help determine the optimal timing 
and frequency of booster immunizations and their role in pertussis control.  
B. Introduction 
 
Widespread immunization against pertussis was implemented using whole-cell 
vaccines in the 1940s and 1950s in many industrialized countries. As a result, the incidence 
of reported pertussis cases decreased 99% in the US by the 1970s1. Despite continuous high 
immunization coverage rates in the US and other industrialized countries, pertussis has 
remained endemic and the incidence of reported pertussis disease has gradually increased 
after reaching a nadir in 19762. Waning of vaccine-acquired immunity and decreased 
opportunities for boosting of immunity due to reduced levels of circulation of Bordetella 
pertussis have been cited as some of the possible reasons for re-emergence of pertussis3-7. 
This article reviews data on the duration of immunity acquired by infection with B. 
pertussis, and duration of immunity acquired by vaccination with whole-cell and acellular 
pertussis vaccines.   
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 C. Duration of immunity acquired by natural infection with B. pertussis 
 
Prior to the implementation of immunization programs, pertussis was widely 
recognized as a severe disease among children. The majority of reported cases occurred in 
children and an estimated 80% of the population suffered from pertussis disease during 
childhood8. Seroprevalence studies in largely unvaccinated populations indicate that almost 
all children (95%) become infected with pertussis by the age of 19 years9.  Selected articles 
describing the duration of potential protection afforded by infection are listed in Table 9.1. 
Adults in the pre-vaccine era rarely presented with typical forms of pertussis10. One 
study indicated that only 0.26% of a population of 20 405 persons had a second case of 
pertussis disease11. It was therefore postulated that immunity from natural infection was close 
to lifelong12, 13. A more recent prospective study of household contacts in a largely 
unvaccinated population demonstrated that 33% of adult pertussis cases had a history of 
pertussis during childhood13. Computer simulations of the pre-vaccine era by mathematical 
modeling estimate that, in 1940, everyone experienced pertussis as a child, 9% of the 
population had more than one typical pertussis episode and the average adult experienced 2.6 
cases of mild pertussis in his/her lifetime14. The frequent occurrence of mildly symptomatic 
B. pertussis infections in adults refutes the previously held belief that infection-acquired 
immunity is lifelong. 
 Symptomatic re-infections with B. pertussis in children have only recently been 
reported, both in the Netherlands and in Senegal. A prospective cohort study in the 
Netherlands documented B. pertussis infection clinically and by laboratory techniques in 
both the first and re-infection episode in 4 children6. The second episodes of pertussis were 
milder than first infections and may not have been diagnosed outside of a research setting. 
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 This study provided well-documented evidence that the duration of infection-acquired 
immunity in children may be as short as 3.5 years A study in Senegal of 8419 children 
documented two episodes of confirmed symptomatic pertussis in 137 unvaccinated children 
(0.02% of 6131 children) and 73 previously vaccinated children (0.03% of 2288 children)15. 
The mean time between the first and second infections was 7.1 years (95% CI: 6.6, 7.6) in 
the unvaccinated children and 5.1 years (95% CI: 4.5, 5.7) in the previously vaccinated 
children. 
The current estimates of the duration of infection-acquired immunity range from 7 to 
10 years15, 16, to 20 years13. These widely different results could be due to differences in 
levels of circulating B. pertussis, surveillance systems, and case definitions used. 
 
D. Duration of immunity acquired by whole cell vaccination 
 
Estimates of the duration of immunity acquired after whole-cell pertussis vaccination 
range from 4 to 12 years4, 7, 10, 12, 17-20 (Table 9.2). These estimates have been derived 
indirectly from various studies, none of which was designed primarily to study the duration 
of immunity. 
 Estimates of duration of immunity following vaccination have been most frequently 
cited based on two studies10, 18. Lambert reported on a 1962 outbreak in Michigan, USA, in 
which 195 cases of B. pertussis infection were identified from 474 household members. 
Vaccination history was collected and attack rates were calculated, demonstrating that 95% 
of the attacks had occurred within 12 years since the last dose of whole-cell pertussis 
vaccine10. Jenkinson, a private physician in the UK, studied a semi-rural community 
consisting of 11 500 people for a period of 10 years and identified 436 cases of pertussis. 
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 Vaccine efficacy was calculated for each age group by excluding the unvaccinated cases and 
subtracting the attack rate (number of cases divided by the number at risk) from one. 
Although children from each age group would have been born in different years, each age 
group was treated as its own cohort. He estimated that by 4 years following immunization, 
only 52% of the children still had a clinically protective level of immunity against pertussis18. 
A recent study based on Australian notification data investigated the effect of age at 
administration of last vaccine dose on the average age of childhood pertussis cases. Australia 
introduced a fifth dose of whole-cell pertussis vaccine at 4 to 5 years of age in late 1994. In 
1997, the peak rate of disease was among 8 to 9-year-olds, while in 2001, the peak rate of 
disease was in 12 to 13-year-olds. This study thus provides evidence that immunity acquired 
by whole-cell pertussis vaccination wanes 6 to 9 years after the last dose7. 
Although vaccine efficacy studies have demonstrated that there is no loss of 
protective immunity following whole-cell vaccination during the first 2 years following 
vaccination21, asymptomatic infections have been reported to occur within the first year 
following vaccination with whole-cell pertussis vaccine22. This indicates that the duration of 
protective immunity against disease lasts longer than the immunity against infection. 
E. Duration of immunity acquired by acellular vaccination 
 
In the 1990s, acellular pertussis vaccine efficacy trials were conducted in various 
countries. In the US, the first acellular pertussis vaccine was licensed for use in 1997. 
Although acellular pertussis vaccines were only recently introduced, some published reports 
on the duration of immunity are available. Results suggest that the duration of protective 
immunity following vaccination with acellular pertussis vaccines is not substantially different 
from that following vaccination with whole-cell pertussis vaccines (Table 9.3).  
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  A prospective surveillance study of participants of a vaccine efficacy study 
comparing two acellular pertussis vaccines demonstrated sustained efficacy of 86% for 
typical pertussis and 76% to 78% for mild pertussis during the first 6 years of life (i.e., more 
than 5 years after the last dose)5. A case-contact study nested in a vaccine efficacy trial 
demonstrated a difference in vaccine efficacy between the acellular and whole-cell pertussis 
vaccines. While in children aged 18 months to 4 years, the pertussis incidence rate was 
higher in those vaccinated with acellular pertussis vaccine compared with those vaccinated 
with whole-cell pertussis vaccine (Incidence Rate Ratio = 1.76; 95% CI: 1.33, 2.33), there 
was no difference in the incidence rate in children younger than 18 months old (Incidence 
Rate Ratio = 1.13; 95% CI: 0.66, 1.95). This may suggest a longer duration of protective 
immunity acquired by whole-cell pertussis vaccination compared with acellular pertussis 
vaccination23.  
In contrast, two studies monitoring the long-term effectiveness of pertussis vaccines 
did not find a difference between the duration of immunity following acellular (two-
component JNIH-6) and whole-cell pertussis vaccine (monovalent Wellcome). In a Swedish 
10-year follow-up study, 13% of the study population acquired pertussis infection, with a 
median age of 5.5 years following the last dose, irrespective of type of vaccine24. In a 
German 6-year follow-up study of whole-cell and acellular vaccines (produced by Wyeth-
Lederle), the calculated efficacy for the 6-year follow-up period was 89% (95% CI: 79, 94) 
for the acellular pertussis vaccine and 92% (95% CI: 84, 96) for the whole-cell pertussis 
vaccine25.  
F. Limitation in addressing duration of immunity 
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 There are many limitations in our understanding of the duration of immunity 
following both natural infection and vaccination. No clear serological marker exists for 
protective immunity against pertussis. By approximately 2 years post-infection or post-
vaccination with either whole-cell or acellular vaccine, antibodies have reached barely 
detectable levels26-29 while immunity against infection remains. 
Levels of circulating B. pertussis in the population have not been controlled in any of 
the studies. This may be important as asymptomatic infections will boost the level of 
immunity and can thus lead to an overestimation of the duration of protection against 
symptomatic disease. Pertussis vaccine efficacy studies have demonstrated a decrease in the 
transmission of B. pertussis infection from vaccinees to household contacts21, 30, 31. 
Observational studies have demonstrated a decrease in B. pertussis incidence rates in 
unvaccinated sub-groups when vaccination coverage is above 80%12, 32-34. The indirect effect 
(or herd immunity) has also not been taken into account in vaccine efficacy studies.  
Another limitation of follow-up of vaccine efficacy trials lies in the difficulty of 
separating vaccine efficacy from waning immunity. If the efficacy of the vaccine is 85%, and 
there is a 20% age-specific attack rate in a highly vaccinated population, waning of immunity 
may have contributed to the occurrence of disease in 5% rather than 20% of the population. 
Nonetheless, the potential overall impact on the population remains considerable.  
Several factors further contribute to the difficulty in measuring the persistence of 
immunity and limit comparability between studies: the use of different vaccines (even within 
the groups of whole-cell or acellular vaccines); changes in manufacturing or vaccine contents 
over time; the presence of different immunization schedules (in timing and/or number of 
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 dosages); and utilization of different case definitions, surveillance methods, and reporting 
systems.  
G. Conclusion 
 
Despite the limitations in measuring persistence of immunity to pertussis disease 
following natural infection or vaccination, some common themes have emerged. Protective 
immunity following infection was probably never lifelong and wanes after 7 to 20 years. 
Duration of immunity following either whole-cell or acellular pertussis immunization does 
not appear to substantially differ and likely lasts 4 to 12 years in children.   Clear differences 
between immunity following vaccination and disease are difficult to distinguish based on 
currently available published data. 
The interplay between waning immunity and boosting of pertussis immunity by B. 
pertussis infection and vaccination influences the epidemiology of pertussis and its 
transmission dynamics in the population. Further research into the rate of waning of vaccine-
acquired immunity will help determine the optimal age and frequency of booster 
immunizations and their role in pertussis control.
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Table 9.1. Selected articles describing duration of protection acquired by natural infection with B. pertussis. 
Author Year Participants (n) Data source Estimate of protection (years) Country of study 
Laing & Hay 1902 20 405 Cohort Near lifelong USA 
Gordon & Hood 1951 Not applicable 
 
Review Near lifelong 
 
Not applicable 
Wirsing von König 
et al. 
1995   369 Prospective
household contact 
20 Germany
Miller & Gay 1997 Not applicable Review/Modeling 7–10  UK 
Versteegh et al. 2002 4 Case series 3.5–12 The Netherlands 
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Table 9.2. Selected articles describing duration of protection acquired by whole-cell pertussis vaccine. 
Author  Year Participants (n) Data source 
Estimate of 
protection (years) Country of study 
Lambert 1965 474 Outbreak (NA) 12 USA (Michigan) 
Jenkinson     
      
    
1988 436 Clinic population
 
4 UK 
CDC 1993 225 Outbreak (NA) 4–6 USA
(Massachusetts) 
Ramsay et al. 1993 3150 Surveillance data 8 UK 
Nielsen & Larsen 1994 Unknown Surveillance data 10 Denmark 
He et al. 1996 3794 Surveillance data 5–10 Finland & 
Switzerland 
Van Buynder et al. 1999 15 286 Surveillance data 5–14 UK 
Torvaldsen & 
McIntyre 
2003 Unknown Surveillance data 6–9 Australia
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Table 9.3. Selected articles describing duration of protection acquired by acellular pertussis vaccine. 
 
Author   Year Vaccine type Participants (n) Data source 
Duration of 
follow-up 
Estimate of 
protection 
(years) 
Country 
of study 
Simondon et al. 1997 Pasteur Merieux 
Serums and 
Vaccines (4-
component) 
4181 Nested case-
contact 
Up to 4.25 
years 
Protection 
following 
whole-cell 
longer than 
acellular 
Senegal 
Tindberg et al. 1999 2-component 207 Follow-up of 
vaccine 
efficacy trial 
10 years 5.5 Sweden 
Salmaso et al. 2001 SmithKline 
Beecham & 
Chiron Biocine 
(Both 3-
component) 
8432  Vaccine
efficacy trial 
3 years 6 Italy 
Lugauer et al. 2002 4-component 10 271 Longitudinal 
cohort 
6 years 6 Germany 
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X. CONCLUSIONS 
A. Summary of Contributions 
 
The focus of this dissertation research has been on identifying the source of 
transmission to young infant cases of pertussis. It has extended the work previously 
conducted in other studies and the study design improved the quality of data collection in 
each of the following aspects. 1) Each infant index case had laboratory confirmation of 
pertussis by either culture or PCR, 2) a comprehensive evaluation of each contact to the 
index case was conducted involving the collection of specimens for PCR, serology (single 
and paired samples), and history of symptoms indicative of pertussis independent of the 
presence of symptoms in the contact, 3) multiple imputation and complete case analyses 
requiring complete enrollment of the household were used to account for missing data, 4) 
sensitivity analyses were conducted to evaluate the impact of the source case definition on 
the ability to identify primary cases, 5) sensitivity analyses were conducted to determine the 
role of serologic criteria used to diagnose pertussis, and 6) the assumption that 
asymptomatically infected individuals are unable to transmit pertussis was explored in order 
to evaluate the potential effect of systematically excluding them in the identification of 
source cases of infant pertussis. 
B. Distribution of source cases for infants with pertussis 
 
This study demonstrates that among infants for whom a source case was identified, 
parents (51%-57%), siblings (17%-22%), and non-household contacts (17%-24%) are 
 important sources of pertussis transmission to young infants. While these findings 
corroborate those from prior studies1-4, they were robust to sensitivity analyses as illustrated 
by the relatively small range (<8%) in point estimates among each stratum of source cases.  
Additionally, this study had fewer limitations than previous studies. The prospective 
study design limited recall error in reporting the timing of symptom onset in contacts. The 
collection of biologic specimens (PCR and serology) for all household members, irrespective 
of symptoms, allowed laboratory confirmation of symptomatic cases and the identification of 
persons with asymptomatic infection. Inclusion of close non-household contacts allowed the 
investigation of their role in pertussis transmission to young infants. Analysis of PCR and 
anti-PT ELISA at a reference laboratory avoided misclassification due to potential inter-
laboratory variation in test performance. The comparatively large sample size and the 
sensitivity analyses conducted allowed confident conclusions about who transmitted 
infection to young infants. 
C. Amount of transmission from casual community contact 
 
This is the first study in the vaccine era to estimate the amount of pertussis 
transmission to young infants due to casual contact from community members. In the 
primary complete case and MI analyses, we found that casual community contact was 
responsible for 31.1% (95% CI=17.6%, 44.6%) and 33.7% (95% CI=23.6%, 43.8%), 
respectively, of pertussis transmission to young infants. These estimates of casual 
transmission are relatively consistent between the complete case and MI analysis which were 
used to address missing data. Specifically, by collecting some data on all non-enrolled 
eligible close contacts (during the first interview with the parents of the infant index case) we 
could build an imputation model allowing for the analysis of all index cases and their 
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 contacts. Consequently, we were able to infer that, in the absence of identifying a source case 
among close contacts of the infant index case, pertussis transmission to these young infants 
was due to casual contact in the community. These results were sensitive to changes in the 
source case definition, resulting in a range of the estimated amount of transmission due to 
casual contact from 19.7% to 47.8%. 
The only other study to estimate the proportion of casual or community transmission 
was performed in the pre-vaccine era. In 1913-1914, Luttinger followed 2,310 pertussis cases 
who attended a whooping cough clinic. The sources of infection, as reported by the guardian, 
were: neighbor (56.8%), relative or friend (17.6%), school or nursery (9.6%), movies, 
recreation pier, roof gardens, ferry, street, and public transportation (4.6%) and unknown 
(11.4%). Thus, exposure from casual community contact accounted for 4.6% to 16.0% of 
transmission5. Considering the important changes widespread vaccination had on the 
epidemiology of pertussis6, the comparison of results becomes somewhat trivial. However, 
one explanation for the observed increase in transmission due to casual contact is that due to 
the >99% reduction in pertussis incidence following widespread vaccination6, the probability 
of knowing somebody with pertussis is much lower today than in the pre-vaccine era; thus 
making the identification of the source case more difficult. Additionally, since in the vaccine 
era the presentation of pertussis in often atypical and mild, pertussis is often not considered 
for diagnosis7. 
D. Impact of the source case definition:  variance in the incubation and infectious 
periods  
 
Two different time periods were used as criteria to define the incubation and 
infectious period of pertussis requiring that symptom onset in the source case must precede 
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 symptom onset in the index case by 2 to 48 days or 7 to 30 days. A source case was 
identified for a greater proportion (14.1%) of infants using the more sensitive time period of 
2 to 48 days than for the 7 to 30 time period. However, the distribution of source cases by 
relationship to the infant was not sensitive to which time period was used. Although the 
source case definition most often used incorporates the time period 7 to 30 days (± 2 days on 
both ends)8-11, the use of a more sensitive case definition is not unprecedented, especially in 
studies most similar to ours. In one study, the source case definition was even more sensitive, 
requiring symptom onset in the source case only to precede symptom onset in the index case 
by at least one day, without an upper limit2. In two other studies, the time period was not 
explicitly stated1, 3.  
The rationale to use the expanded period of infectiousness and shorter incubation 
period was based on data from Stocks12 where cough plates were used to determine the start 
and end of the infectious period among sequential cases within a household. An additional 
study of early vaccine efficacy reported similar results13. In our study, we identified a 
substantial number of source cases with symptom onset 2-6 days and 31-48 days prior to 
symptom onset in the index case. 
E. Impact of source case definition: transmission from asymptomatic individuals 
 
A change in the source case definition allowed individuals with laboratory confirmed 
asymptomatic infection to be source cases in the absence of identifying a symptomatic source 
case in one of the sensitivity analyses. Similar to the results from other sensitivity analyses, 
the proportion of infants for whom a source case was identified was sensitive to this change 
(as a source case was identified for an additional 14.0% of index cases); however, the 
distribution of source cases among those where a source was found was not sensitive. 
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 Although asymptomatic infection has been previously documented14-16, it is generally 
believed that transmission from individuals with asymptomatic infection does not occur since 
these individuals do not cough or sneeze and thus do not generate the infectious aerosol 
droplets necessary for efficient spread to others17. However, in the context of infant pertussis 
where respiratory secretions may be shared through activities such as kissing, cuddling, and 
singing, it is plausible that transmission may occur. These findings indicate that if one 
accepts that such transmission occurs, accounting for transmission from close contacts with 
asymptomatic infection becomes important in identifying the source of infant pertussis. 
F. Impact of diagnostic criteria in diagnosing pertussis 
 
In an effort to estimate the minimum proportion of infant transmission due to casual 
contact in the community, we increased the sensitivity of the diagnostic methods and case 
finding definition as much as possible. In one sensitivity analysis, increasing the sensitivity 
of paired serologic test by using a 2-fold change in paired anti-PT titer instead of a 4-fold 
change had not impact on the identification of source cases. In a similar sensitivity analysis 
to increase the sensitivity of the single serum test, lowering the cut-off value from 125 
EU/mL to 100 EU/mL had minimal impact as, on average, only one additional source case 
was identified. Finally, the more sensitive PCR target IS481 was employed over the more 
specific PT target18. 
G. Evaluation of vaccination strategies 
 
The study results are important in evaluating the impact of current pertussis 
vaccination strategies and predicting the effect of new vaccination strategies on infant 
pertussis. This study corroborates the findings from Olin et al.19 that infant vaccination 
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 protects against hospitalization. Of hospitalized infants, 60% were non-vaccinated, 37% had 
received 1 dose, and 3% had received 2 doses. While it is vital to maintain high coverage 
rates and timely vaccination of infant and children against pertussis, we did not find that non-
vaccination of siblings was a driving force for infant pertussis. Although adolescents (aged 
13 to 18) accounted for 16.3% of the identified primary cases (of which 10% were non-
household contacts and 6% were siblings), their relative role in transmission may be greater 
as 66% of infants did not have an adolescent contact. The recently recommended routine 
adolescent vaccination strategy in the U.S. may therefore not only have an important direct 
effect on adolescent pertussis, but will also likely play a role in combating infant pertussis. 
The impact of routine adult vaccination will depend on the coverage rate among adults who 
come in close contact with young infants and may also reduce infant pertussis. 
In this population of young children, our study did not provide evidence for targeting 
non-relative caretakers, as their role was smaller than expected with only 1 (2.0%) part-time 
caretaker and no full-time caretakers being identified as the source. While some relatives 
(grandparents, aunts, etc.) may play the role of part-time caretaker, they defined their 
relationship with the infant as relatives rather than caretakers. 
H. Limitations 
 
Inherent to pertussis research, this study was limited by the lack of a highly sensitive 
and specific (gold standard) diagnostic test. However, the state-of-the-art diagnostic methods 
(PCR and serology) were used to conduct a comprehensive evaluation of each identified 
close contact in an effort minimize the effects of pertussis outcome misclassification.   
Missing data due to non-participation and refusal to provide diagnostic specimens 
among participants was an additional limitation. In an effort to address missing data, a 
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 complete case analysis and the more sophisticated statistical method using MI were 
employed. Unfortunately no analytic method, including MI, is able to prove the missing data 
mechanism was non-ignorable (i.e., missingness was not dependent on source case status). 
For simplicity, we assumed an ignorable missing data mechanism. To assess the validity of 
this assumption we used symptoms as a proxy measure for being a source case (as it is a 
prerequisite for being a source case in the main analysis) and found that, although not 
statistically significant, participants with missing data and non-participants were less likely to 
be symptomatic than participants with complete data (OR=0.69 (95% CI=0.39, 1.20) and 
OR=0.70 (95% CI=0.40, 1.22), respectively). We interpret this to suggest that the missing 
data mechanism was non-ignorable. However, if source cases were more likely to be enrolled 
than non-source cases, the results would not be biased due to systematic non-enrollment of 
source cases. Ideally a validation study should be conducted to determine the nature of the 
missing data mechanism, thus allowing the empirical specification of the model for the 
missing data mechanism20. 
I. Future Research 
 
The findings from this dissertation indicate that additional research is needed to 
derive the optimal source case definition as the results were sensitive to varying the lengths 
of the incubation and infectious periods. Similarly, a study designed to provide direct 
evidence regarding the possibility of transmission from individuals with asymptomatic 
infection is essential to more precisely estimating the amount of transmission due to casual 
contact.  
The introduction of the newly licensed pertussis boosters for adolescents and adults 
will almost certainly make important changes on the epidemiology of pertussis. Thus, 
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 enhanced surveillance among infants, adolescents, and adults is essential to measuring the 
impact this additional vaccination will have on infant pertussis.  
J. Conclusions 
 
In conclusion, this study provides robust evidence that, among infants where a source 
case could be identified, household members were responsible for 73% to 82% of 
transmission of Bordetella pertussis to infants, of whom parents account for 67% to 70% and 
siblings account for 22% to 28%.  
While it is imperative to maintain high vaccination rates among the infant and 
childhood doses, there is no evidence that low immunization rates among children were 
responsible for pertussis transmission to young infants. However, the findings that the 
combined amount of transmission due to adolescents (16% to 22%) and adults aged 19 to 39 
years (54% to 61%) accounted for 70% to 77% of transmission to young infants reinforces 
the recent recommendation by the U.S. Advisory Committee on Immunization Practices 
(ACIP) that all adolescents and adults receive a booster dose of Tdap (tetanus toxoid, 
reduced diphtheria toxoid and acellular pertussis vaccine) in place of Td (tetanus and 
diphtheria toxoids vaccine)21. Thus, routine adult and adolescent vaccination have the 
potential to reduce a substantial proportion of the burden of infant pertussis if high coverage 
rates, especially among those in close contact with young infants can be achieved.  
This study presents evidence that casual contact from the community is responsible 
for 20% to 48% (including confidence intervals (11% to 59%)) of pertussis transmission to 
young infants. This proportion is higher than a report from the pre-vaccine era and may be 
due to an unawareness of pertussis and a strikingly lower incidence of pertussis. Multiple 
imputation analysis was used to account for missing data due to non-participation and 
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 missing diagnostic specimens among participants. Although missingness was limited in this 
study (<10% of symptomatic contacts), properly accounting for this missing data was a 
unique strength of these analyses.   
The public health message that pertussis is extremely contagious, even among 
vaccinated populations, is underscored by the finding that the prevalence of pertussis was 
>60% in this population. The findings of an appreciable proportion of laboratory confirmed 
asymptomatic pertussis cases may also contribute to better understanding the epidemiology 
of infant pertussis.  
Finally, the results concerning the distribution of identified source cases were robust 
to changes in the sensitivity of the source case definition. However increasing the sensitivity 
of the source case definition (including varying the incubation and infectious periods and 
allowing asymptomatically infected persons to be source cases) resulted in an important 
increase in the proportion of infants for whom a source case was identified. 
Understanding who infects young infants with B. pertussis, including the proportion 
due to casual community contact, will be important in evaluating the effectiveness of the new 
adolescent and adult vaccination strategies on the control of infant pertussis. 
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 XI. APPENDIX I 
A. Adult informed consent 
 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Adult Subjects 
________________________________________________________________________ 
IRB Study #_____________________  
Consent Form Version Date: August 22, 2002  
 
Title of Study: Household transmission of Bordetella pertussis – who infects young infants? 
 
Principal Investigator: Annelies Van Rie, MD, PhD  
UNC-CH Department: Epidemiology 
Phone number: (919) 966-1420 
 
Co-Investigators:  
1. Scott Halperin, MD, Pediatric Infectious Diseases,IWK Health Centre, Halifax Nova Scotia, 
Canada  
2. David Greenberg, MD Children’s Hospital of Pittsburgh, Pittsburgh, USA 
3. Antoinne Bourollon, MD Hôpital Robert Debré, Paris, France 
4. Joel Gaudelus, MD Hôpital Jean Verdier, Bondy, France 
5. Emmanuel Grimpel, MD Hôpital Armand Trousseau, Paris, France 
6. Daniel Floret, MD Hôpital Edouard Herriot, Lyon, France 
7. Nicole Guiso, MD Bordetella Laboratory, Institut Pasteur, Paris, France 
8. Other U.S. and Canadian sites to be determined 
 
Sponsor: Aventis Pasteur 
________________________________________________________________________ 
 
You are being asked to take part in a research study.  The investigators listed above are in 
charge of the study; other professional persons may help them or act for them. 
 
What are some general things you should know about research studies? 
 
Research studies are designed to gain scientific knowledge that may help other people in the 
future.  You may not receive any direct benefit from participating. There may also be risks 
associated with participating in research studies. 
 
Your participation is voluntary.  You may refuse to participate, or may withdraw your 
consent to participate in any study at any time, and for any reason, without jeopardizing your 
future care at this institution or your relationship with your doctor.  If you are a patient with 
an illness, you do not have to participate in research in order to receive treatment. 
 
Details about this particular study are discussed below.  It is important that you understand 
this information so that you can decide in a free and informed manner whether you want to 
participate.  You will be given a copy of this consent form.  You are urged to ask the 
 147
 investigators named above, or staff members who may assist them, any questions you have 
about this study at any time. 
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 What is the purpose of this study?  
The purpose of this research study is to determine the role of close contacts (parents, 
siblings, caretakers) in transmitting whooping cough to infants. You are being asked to 
participate in this study because your child/a child with whom you have close contact 
has been diagnosed with whooping cough disease.  
 
How many subjects will participate in this study? 
A total of approximately 105 subjects (infants and their contacts) at 9 institutions will take 
part in this study, including approximately (number) subjects from this institution. 
 
How long will your participation last?  
Your participation in this study will last for 2 visits of  
- One parent: approximately 1 hour and 15 minutes approximately 
- Other contacts: approximately 15 minutes     
   
What will happen if you take part in the study? 
During the course of this study, the following will occur: 
If you agree, there will be two visits for this study for each close contact of the infant, the second visit 
being four weeks after the first visit. At the first visit, we will take a blood sample of approximately 3 
mL (about a teaspoon) from a vein and a respiratory sample (liquid from your nostrils or sputum) in 
order to detect signs of the presence of the bacteria that causes pertussis. You will also be asked 
questions concerning your health and medical history. At the second visit we will take another blood 
sample of approximately 3 ml from your vein and ask you a few more questions concerning your 
health. 
 
Are there any reasons you should not participate? 
You should not participate in this study if you live far from the study site.  
 
What are the possible risks or discomforts?  
The collection of blood and respiratory specimen might involve some discomforts to you. 
 
What are the possible benefits? 
Persons who accept to participate in the study will benefit directly. They will be tested for the 
whooping cough bacteria and given the appropriate antibiotic treatment. This can reduce the 
duration and severity of symptoms and will help to stop the transmission of the bacteria 
within and outside the family set-up.  
 
From a public health perspective, results of this study may help propose better 
recommendations to improve the vaccine schedule for pertussis and reduce the 
suffering of pertussis.  
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 How will your privacy be protected? 
No subjects will be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state 
law requires the disclosure of such records, including personal information.  This is very 
unlikely, but if disclosure is ever required, UNC-CH will take all steps allowable by law to 
protect the privacy of personal information. 
 
Records will be kept in a secured place. No names will be used, only initials and a coded 
number. The sponsor, Aventis Pasteur may review all records.   
 
Will you be paid for participating? 
You will not be paid for your participation in this study.  
 
Will it cost you anything to participate? 
The costs of this research will be paid by the sponsor. 
 
Who is sponsoring this study? 
This research is funded by Aventis Pasteur.  This means that the research team is being 
compensated by the sponsor for conducting the study.  The researchers do not, however, hold 
a direct financial interest in the sponsor or in the outcome of the study. 
 
What will happen if you are injured by this research? 
All types of research involve possible risk. The sponsor has set aside funds to compensate 
you for any such complications, injuries or related medical care. However, by signing this 
form, you do not waive any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have further questions, or if a research-related injury occurs, you should call  
(name and degree of investigator)  at  (phone number) . 
 
What if you have questions about your rights as a subject? 
This study has been reviewed and approved by the School of Public Health Institutional 
Review Board on Research Involving Human subjects.  If you have questions about your 
rights as a study participant, or are dissatisfied at any time with any aspect of this study, you 
may contact – anonymously, if you wish – the school of Public Health Institutional Review 
Board, University of North Carolina at Chapel Hill, CB# 7400, Chapel Hill, NC 27599-7400, 
or by phone 919-966-3012.  You may call collect. 
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Subject’s Agreement: 
 
I have read the information provided above. I voluntarily agree to participate in this study.  
 
_________________________________________   _________________ 
Signature of Research Subject     Date 
 
_________________________________________ 
Printed Name of Research Subject 
 
_________________________________________  _________________ 
Signature of Person Obtaining Consent   Date 
 
_________________________________________ 
Printed Name of Person Obtaining Consent 
 
IRB Approval Date:_________________________ Expiration Date:_____________ 
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 B. Child informed consent 
 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Parents of Minor Subjects                          
________________________________________________________________________ 
IRB Study #_____________________   
Consent Form Version Date: August 22, 2002 
 
Title of Study: Household transmission of Bordetella pertussis – who infects young infants? 
 
Principal Investigator: Annelies Van Rie, MD, PhD 
UNC-CH Department: Epidemiology 
Phone number: (919) 966-1420 
 
Co-Investigators:  
1. Scott Halperin, MD, Pediatric Infectious Diseases,IWK Health Centre, Halifax Nova Scotia, 
Canada  
2. David Greenberg, MD, Children’s Hospital of Pittsburgh, Pittsburgh, USA 
3. Antoinne Bourollon, MD, Hôpital Robert Debré, Paris, France 
4. Joel Gaudelus, MD, Hôpital Jean Verdier, Bondy, France 
5. Emmanuel Grimpel, MD, Hôpital Armand Trousseau, Paris, France 
6. Daniel Floret, MD, Hôpital Edouard Herriot,  Lyon, France 
7. Nicole Guiso, MD, Bordetella Laboratory, Institut Pasteur, Paris, France 
8. Other U.S. and Canadian sites to be determined 
 
Sponsor: Aventis Pasteur 
________________________________________________________________________ 
 
You are being asked to allow your child to take part in a research study.  The investigators 
listed above are in charge of the study; other professional persons may help them or act for 
them. 
 
What are some general things you should know about research studies? 
 
Research studies are designed to gain scientific knowledge that may help other people in the 
future.  Your child may not receive any direct benefit from participating. There may also be 
risks associated with participating in research studies. 
 
Your child’s participation is voluntary.  You may refuse to allow this participation, or may 
withdraw your consent at any time, and for any reason, without jeopardizing your family’s 
future care at this institution or your relationship with your doctor.  If your child is a patient 
with an illness, your child does not have to participate in research in order to receive 
treatment. 
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 Details about this particular study are discussed below.  It is important that you 
understand this information so that you can decide in a free and informed manner 
whether you want your child to participate.  You will be given a copy of this consent 
form.  You are urged to ask the investigators named above, or staff members who may 
assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
The purpose of this research study is to determine the role of close contacts (parents, siblings, 
caretakers) in transmitting whooping cough to infants. You are being asked to participate in 
this study because your child/a child with whom you have close contact has been diagnosed 
with whooping cough disease.  
 
How many subjects will participate in this study? 
A total of approximately 105 subjects (infants and their contacts) at 9 institutions will take 
part in this study, including approximately (number) subjects from this institution. 
 
How long will your child’s participation last?  
Index case: Your child’s participation in this study will last for approximately 0 minutes. We 
will ask only ask questions to you. There are no procedures related to the study in your infant 
Child contact of index case: Your child’s participation in this study will last for 
approximately  2 times 15 minutes.  
   
What will happen if your child takes part in the study? 
During the course of this study, the following will occur: 
If you agree, there will be two visits for this study for each close contact of the infant, the second visit 
being four weeks after the first visit. At the first visit, we will take a blood sample of approximately 3 
mL (about a teaspoon) from a vein and a respiratory sample (liquid from your nostrils or sputum) 
from your child in order to detect signs of the presence of the bacteria that causes pertussis. You will 
also be asked questions concerning your health and medical history. At the second visit we will take 
another blood sample of approximately 3 ml from your vein and ask you a few more questions 
concerning your child’s health 
 
What are the possible risks or discomforts?  
The collection of blood and respiratory specimen might involve some discomforts to you. 
 
What are the possible benefits? 
The benefits to your child of participating in this study may be that they will be tested for the whooping cough 
bacteria and given the appropriate antibiotic treatment. This can reduce the duration and 
severity of symptoms and will help to stop the transmission of the bacteria within and outside 
the family set-up.  
From a public health perspective, results of this study may help propose better 
recommendations to improve the vaccine schedule for pertussis and reduce the 
suffering of pertussis.  
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 How will your family’s privacy be protected? 
No subjects will be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state 
law requires the disclosure of such records, including personal information.  This is very 
unlikely, but if disclosure is ever required, UNC-CH will take all steps allowable by law to 
protect the privacy of personal information. 
 
Records will be kept in a secured place. No names will be used, only initials and a coded 
number. The sponsor, Aventis Pasteur may review all records.   
 
Will you or your child be paid for participating? 
Your child will not be paid for participating in this study.  
 
Will it cost you anything if your child participates? 
There will be no costs for your child for participating.  
 
Who is sponsoring this study? 
This research is funded by Aventis Pasteur.  This means that the research team is being 
compensated by the sponsor for conducting the study.  The researchers do not, however, hold 
a direct financial interest in the sponsor or in the outcome of the study. 
 
What will happen if your child is injured by this research? 
All types of research involve possible risk, some including the risk of personal injury. The 
sponsor has set aside funds to compensate you for any such complications or injuries, or for 
related medical care. However, by signing this form, you do not waive any of your legal 
rights. 
 
What if you want to stop before your child’s part in the study is complete? 
You can withdraw your child from this study at any time, without penalty.   
  
What if you have questions about this study? 
You and your child have the right to ask, and have answered, any questions you may have 
about this research. If you have further questions, or if a research-related injury occurs, you 
should call  (name and degree of investigator)  at  (phone number) . 
 
What if you have questions about your child’s rights as a subject? 
This study has been reviewed and approved by the School of Public Health Institutional 
Review Board on Research Involving Human subjects.  If you have questions about your 
rights as a study participant, or are dissatisfied at any time with any aspect of this study, you 
may contact – anonymously, if you wish – the school of Public Health Institutional Review 
Board, University of North Carolina at Chapel Hill, CB# 7400, Chapel Hill, NC 27599-7400, 
or by phone 919-966-3012.  You may call collect. 
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 Parent’s Agreement: 
 
I have read the information provided above. I voluntarily agree to allow my child to 
participate in this study.  
 
_________________________________________ 
Printed Name of Research Subject (Child) 
 
_________________________________________   _________________ 
Signature of Parent       Date 
 
_________________________________________ 
Printed Name of Parent 
 
_________________________________________  _________________ 
Signature of Person Obtaining Consent   Date 
 
_________________________________________ 
Printed Name of Person Obtaining Consent 
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